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ABSTRACT

The population approach to pharmacokinetic analysis, and its application to the
identification of patient characteristics that affect a drug's pharrnacokinetic parameters,
is achieving greater prominence in the drug development process. Specifically,
population analyses are a way to gather information that might be difficult to capture in
some subpopulations. In the fall of 1997, the Food and Drug Administration proposed
new legislation, commonly known as the ''Pediatric Rule". This new legislation required
pharmaceutical companies to collect pediatric data for drugs with indications applicable
to children before the compound would be approved. Other than conducting traditional
pharrnacokinetic clinical trials, another way to collect this information would be to
perform a population pharrnacokinetic analysis. Two different examples ofthis approach
are presented. The first study was conducted on traditional pharrnacokinetic data
(intense sampling) pooled from four pediatric trials. The second study is an example of
the ability of the population approach to take advantage of sparse data obtained as a
secondary objective of a clinical study.

A population pharrnacokinetic analysis was conducted for azithromycin on data from
pediatric patients enrolled in four separate clinical trials. A two compartment model with
parallel zero- and first-order absorption was found to best fit the data. Potential
covariates were assessed for oral clearance (CL/F), oral volume of distribution in the
peripheral compartment (V2/F), intercompartmental oral clearance (Q/F), and the first-

order absorption rate constant (ka). Weight was found to be a significant covariate for
both CUF and V2/F. No covariates were found to be significant for Q/F or ka.

A population pharrnacokinetic analysis was conducted for prednisolone on data from
thoracic organ transplant patients. A one compartment model with a fixed first order
rate of absorption was found to best fit the data. Potential covariates were assessed for
oral clearance (CUF) and oral volume of distribution (V/F). Sex and concomitant
ciprofloxacin use were found to be significant covariates for CUF. No covariates were
found to be significant for VIF. Data was also available on plasma concentrations of
prednisolone' s metabolite, prednisone. It was not possible to derive a robust and
clinically meaningful model that incorporated the metabolite data.
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PREFACE

This document was prepared in the format of the manuscript plan in accordance to
section 11-10 of the Graduate School Manual at the University of Rhode Island. The
dissertation is divided into three sections.

Section I contains a general introduction to the objectives of the research. Section II
consists of the main body of this dissertation. This section is composed of three
manuscripts written in the format required for each scientific journal to which they are,
or will be submitted. A statement of overall conclusions for the entire dissertation is also
included in this section. Section III contains one appendix that includes additional
information and experimental details useful to the understanding of the work in Section
11. A bibliography follows Section III in which all sources used as references in this
document are cited.
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INTRODUCTION

ln February 1999 the Food and Drug Administration (FDA) issued a final guidance
governing the development, conduct, and analysis of population pharmacokinetic clinical
trials (I). The guidance states that population phannacok:inetic analyses are ideal to
investigate variability and alternative dosing regimens when there is prior knowledge that
certain factors may affect drug behavior. Traditionally, alternative dosing regimens have
required a large clinical trial or many smaller clinical trials in sub-populations. lnstead of
running additional clinical trials, the FDA guidance has suggested that an alternate
method of analysis, population pharmacokinetic analysis, may provide the same
information.

The need to modify the usual dose of a drug in certain populations is determined by
comparing the pharmacokinetics of the sub-group to the population as a whole. There
may be so many different sub-populations that it is often unrealistic to run a separate
clinical trial for each group. Many times, dosages are adjusted empirically across subpopulations; using either clinician experience or assuming dose proportionality with
either body weight or age. These empirical approaches increase the tendency for serious
adverse events or sub-therapeutic concentration levels (2;3). In order to address the
inadequate dosing information, many researchers have been focusing on new approaches
to pharmacokinetic analyses and model building.

Originally, pharmacokinetic modeling concentrated on the individual For example, in a
traditional standard two stage analysis (STS), a clinical trial is comprised of a small
number of subjects from whom a large (12-20) number of serial blood samples are
collected over a dosing interval. Trials are restricted to representative subjects from a
particular population to limit variability between subjects. An analysis of this type of
data is done in two stages. For the first stage, plasma concentration time data are
modeled using nonlinear regression to produce estimates of the pharmacokinetic
parameters. For the second stage, the individual pharmacokinetic parameters are
combined and descriptive summary statistics are computed (e.g. group mean and group
variance). Analysis of the dependencies between the parameter and any covariates use a
classical statistical approach (stepwise linear regression, cluster analysis, etc.) (1 ;4;5).
This type of analysis moves from an individual (unit of analysis) out to the population,
and as a result, the parameter estimates are unbiased and the random effects are
overestimated (I). There are several logistical issues associated with this approach,
primarily revolving around the need to perform extensive blood sampling and
homogeneity of the population ( 1;6). These reasons have led to an alternative approach
known as nonlinear mixed effects modeling.

A second approach, nonlinear mixed effects modeling, is a way to directly study the
population' s pharmacokinetics. Nonlinear mixed effects modeling is less stringent than a
STS analysis; it allows for the use of sparse data (2 or more samples not necessarily from
the same dosing interval per patient) from a large number ofrepresentative patients in
the population (I ;4;5;7). The population method pools aU data collected and calculates
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population pharmacokinetic parameters (e.g. volume of distnbution). Additionally the
focus of the analysis is on the source and correlation of variability in drug concentrations
among individuals in the population. Thus, population pharmacokinetics focuses on the
target population (unit of analysis) and moves out to the individual. Population analyses
also provide quantitative estimates of both the interindividual and intraindividual
variabilities of the population (4;5). Interindividual variability may be accounted for by
adding specific patient characteristics into the population model. Patient characteristics
that cause changes in the dose-concentration relationship can be identified and assessed
and then appropriate dosing modifications can be determined (1).

Nonlinear mixed effects modeling will be performed using a software package called
NONiinear Mixed Effect Model (NONMEM) version 5 level I. I. NONMEM is suitable
to analyze these types of data and has been extensively utilized by others (8;9). Both
fixed and random effects are modeled using NONMEM. Fixed effects (e.g. time or
dose) structure the actual pharmacokinetic parameters (structural portion of model).
Random effects are comprised of random interindividual variability (unexplainable error
produced by each individual's variability not accounted by the fixed effects) and
intraindividual variability (explainable error accounting for the difference between actual
and predicted concentration values) in the pharmacokinetic parameters (statistical
portion of model). NONMEM provides estimates of both inter- and intraindividual (i.e.
residual random error) variabilities in the pharmacokinetic parameters (4;7;9).

HYPOTHESIS TESTED

To date, there are no published population pharmacokinetic models for azithromycin in
the pediatric population and prednisolone in organ transplant patients. For azithromycin,
small clinical trials have been conducted in pediatric patients to determine alternative
dosing regimens. The drug's label includes results from some of these trials and only has
information on adjusting dose by weight (kg). For prednisolone, it appears that a
standard dose produces a large variability in prednisolone concentrations. There is little
information on the cause of this variability and on what adjustments should be made to
doses in certain sub-populations. For the use of prednisolone in organ transplant
patients, it is critical that an optimum prednisolone concentration be achieved. It has
been shown that a patient with a higher prednisolone clearance is more likely to suffer an
allograft loss, while a patient with high prednisolone concentration levels (i.e. low
prednisolone clearance) is more likely to suffer from adverse events (2;10) .

The hypothesis to be tested in this investigation is that the population pharmacokinetic
modeling approach can be used to evaluate and describe the concentration time data
collected in the azithromycin and prednisolone clinical trials. Using this approach,
precise est·imates of the pharmacokinetic parameters and their variability will be
quantifiable and significant covariates will be identified.
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OBJECTIVES

The specific aims ofthis dissertation are as follows:
Azithromycin example:
I) To develop a population pharmacokinetic model for pediatric patients taking
azithromycin. This model will include the following pharmacokinetic parameters:
clearance (CUF), volume of distribution (VD/F), interindividual variability, and
intraindividual variability.
2) To identify individual characteristics such as demographic information, disease
status, and concomitant medications which effect values of pharrnacokinetic
parameters.

Prednisolone example:
3) To develop a population pharmacokinetic model for prednisolone including oral
clearance (CUF) and oral volume of distribution (II IF) and to assess the
interindividual variability in thoracic organ transplant patients
4) To investigate various individual characteristics such as demographic information,
disease status, and concomitant medications as potential covariates to reduce
interindividual variability
5) To develop a population pharmacokinetic model for the evaluation of the optimal
prednisolone dosing based on individual characteristics.
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MANUSCRIPT I

Summary of Recent Proposed Regulation for Assessment of Safety and
Effectiveness of Drugs and Biological Products in the Pediatric Population
Published in Clinical Research and Regulatory Affairs 15(2):79-90. 1998

ABSTRACT
In the fall of 1997, the United States Food and Drug Administration (FDA) proposed to
add onto the existing 1994 regulations dealing with the "pediatric use" subsection of
prescription drug labels. These new regulations were titled Docket No. 97N-0165
"Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New
Drugs and Biological Products in Pediatric Patients"(!). These new rules will require
pharmaceutical companies to collect data for those drugs whose indications may be
applicable to usage in children before the compound will be approved (or soon
thereafter). In some cases, manufacturers will also have to provide this information
(within a length of time determined by both the FDA and the manufacturer) for drugs
already marketed. It is proposed that, by including safety and effectiveness information
on the label, the pediatric population will be less likely to have serious adverse events or
subtherapeutic treatments. This article will cover in detail the 1997 proposed regulations
and what it will mean for industry.

INTRODUCTION
The United States Food and Drug Administration (FDA) claims that pediatric labeling
often is incomplete, inadequate, and even nonexistent for many prescription drugs. In
most cases, the label contains no information on safe and effective doses for children. To
address this issue, FDA passed regulations in December of 1994 which made it easier for
manufacturers to include pediatric information in the "pediatric use" subsection of
prescription drug labels. The 1994 regulations amended an earlier set of regulations
from 1979 requiring fuU clinical trials in the pediatric population as a basis for labeling
for use in this population. The 1994 legislation built on to the 1979 regulations with
three points: I) data could be extrapolated from adult studies, if the course of the
disease and the drug effects were similar in both the pediatric and adult populations, 2)
companies had to reexamine data to determine whether pediatric labeling of their
marketed products needed to be modified, and 3) FDA was given authority to request
specific pediatric use information. The purpose of these regulations was to make it
easier for manufacturers to include pediatric information on the labeling of their
products. Although the Pharmaceutical Research and Manufacturers of America
(PhRMA) believes that industry has been in compliance with the regulations (2), the
FDA believes many companies are still not providing adequate information (Proposed
Rule Section II (1)). Consequently, in the fall of 1997, FDA proposed new regulations to
address what it perceives as the pharmaceutical industry's poor compliance to the I 994
regulations.

Post 1994 Regulations to Present
FDA states clinical studies in the pediatric population have been conducted for only a
small fraction of drugs currently on the market. The labeling of many of these drugs
contain limited, if any, information on either the use of the drug in the pediatric patient or
on specific dosing requirements for the different pediatric age groups. The FDA
conducted a survey and found that although there was adequate pediatric labeling for
vaccines and antibiotics, the labeling for many drugs used to treat common childhood
illnesses and other more serious conditions, contained little information fo r pediatrics.
From data collected by IMS America, Ltd. regarding prescription drug usage, FDA
compiled the I 0 most prescribed drugs in pediatric patients, on an outpatient basis (Table
I). For these I 0 drugs, FDA claims the label either lacked information for the
subpopulation for which the drug was being prescribed, or the information was
inadequate (Proposed Rule, Section I (1)). PhRMA responded to these claims by noting
that the data was obtained in 1994 and therefore out-dated. After 1994, the
manufacturers claim that either they have provided additional pediatric information
within the label or that there is no need for additional labeling information- particularly
for Ampicillin and Auralgan (2). The Center for Drug Evaluation and Research (CDER)
identified the top ten drugs prescribed (on both an inpatient and outpatient basis) in the
pediatric population and asked the companies that market these drugs to voice their
concerns over the proposed changes in regulations (Proposed Rule, Section 11 (I)).
FDA claims that physicians have to either guess on an appropriate dosage (causing a
potential for subtherapeutic levels or adverse events due to toxicity) or prescribe only
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those drugs with which they have had experience prescribing in the pediatric population
(causing a potential for a less effective form of therapy) (Proposed Rule, Section I (I)).

An informal study by the American Academy of Pediatrics in 1990 found that only 20%
of the new molecular entities (NME's) approved between 1984-1990 had pediatric
information (not all of the NME' s had potential use in the pediatric population) and that
56% of the NME's approved in 1991 that had potential use in the pediatric population
had some pediatric labeling at the time of approval. In 1996 (2 years after the passing of
the 1994 regulations regarding pediatric use labeling) only 37% of the NME's that had
potential use in the pediatric population had some pediatric labeling at the time of
approval. The pediatric labeling that was present on the NME's in 1991 and 1996 may
not have been adequate for all groups within the pediatric population (Proposed Rule
Section lII (1)). PhRMA states that 20 of the approved drugs in 1996 would have
potential use in the pediatric population. Of these 20, 19 have been studied or will be
studied in pediatric patients, showing an improvement in industry' s response to the 1994
regulations (2).

Description of the Proposed Rule
The proposed rule would be intended for new chemical entities and new biological drug
products. A new chemical entity is defined as "a drug that contains no previously
approved active moiety." There are three main points to this proposed rule: 1) before
approval, a new chemical entity must have safety and efficacy information on relevant
pediatric age groups for the claimed indication, 2) drugs already marketed will need to
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provide more pediatric information if the label is lacking in relevant information, and 3)
FDA can call for meetings to discuss the need for pediatric studies early in the
development process and postmarketing. FDA bas broken down the pediatric
population into 4 subgroups: I) neonates- birth to one month of age, 2) infant- one
month to two years of age, 3) children - two years to twelve years of age, and 4)
adolescent - twelve years to sixteen years of age. A safety and efficacy assessment
would be required for pediatric patients, in all age groups, for the claimed indication. A
manufacturer. would not be responsible for providing information for any off-label
indications. Companies would not need to provide new information for any supplements
filed for new indications (Proposed Rule Section V.A (l)).

Pediatric formulations would be required in the studies to ensure bioavailability and the
consistency of the dosing. By using a pediatric formulation in a study, data will be more
meaningful and an accurate analysis can be made for safety and effectiveness in the
pediatric population. If a manufacturer were unable to produce an appropriate pediatric
formulation for a given age group, then a waiver would be granted. FDA was seeking
comments on using cost of generating a formulation to be grounds for a waiver
(Proposed Rule Section V.E (!)).

Waivers
Pediatric studies would not be necessary if FDA granted a full or partial waiver
(Proposed Rule Section V.B.4 (!)). Pediatric assessments are not necessary if I) the
product will not be a meaningful therapeutic benefit over already existing treatments and
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if it will not be widely used in the pediatric population, 2) if studies would be impossible
or impractical to carry out, and 3) ifthe compound would pose undue risk to the
pediatric patients. A full waiver would be granted if one or more of the conditions above
applied to the entire pediatric population. A partial waiver would be granted if there was
a need to avoid studies in a specific age group within the pediatric population. FDA was
seeking comments regarding whether there should be other situations that might merit a
waiver - e.g. costs.

One of the questions that FDA faced was how to quantify "meaningful therapeutic
advances" . FDA addressed this issue by deciding that it would be meaningful if a
substantial number of patients were to use this new compound. The proposal discusses
two different methods for determining a substantial number of patients. The first method
would be to assess the number of times the drug would be used annually within the
pediatric population. If it is estimated that I 00,000 or more prescriptions may be written
for patients within the pediatric population, then the drug would qualify as being given to
a substantial number in all age groups. A partial waiver would be granted if fewer than
I 5,000 prescriptions were to be written for a specific age group. The second method
would assess the number of patients affected by the disease or condition that the drug is
designed to treat. If I 00,000 pediatric patients were affected, then the compound would
be used in a substantial number of pediatric patients. A partial waiver would be granted
if fewer than I 5,000 patients comprised a particular age group (Proposed Rule Section
V.B.4 (I)). PhRMA argues over the true representation of the diseased population by
using prescription numbers as a basis for calculating a drug as being used in a substantial

13

number of patients. For many diseases (e.g. asthma) multiple prescriptions are refilled
several times in a given year for a single patient. PhRMA believes that there would be
potential for gross exaggerations of diseased children for certain diseases. PhRMA
recommends deciding a meaningful therapeutic advance by unmet medical needs and not
by arbitrarily decided numbers which may not be a true measurement of the diseased
population (2) .

There may be instances where the deferral of submissions of pediatric studies may be
necessary (e.g. if the New Drug Application (NOA) submission or approval is ready for
adults before pediatric testing is complete). It may be inappropriate to begin pediatric
testing before the safety and efficacy data in adults has been collected. The deferred
submission would need to be provided not more than 2 years after the date of the initial
approval. Applicants would need to provide pediatric information in their Annual
Progress Reports (APRs) to show compliance (Proposed Rule Section V.B.3 (1)).

Legal Ramifications for Inadequate Pediatric Labeling Information
In the proposed rule, FDA states "Denying or withdrawing approval of an otherwise safe

and effective drug or biological product is not a satisfactory remedy, because removal of
a product from the marketplace could deprive other patients of the benefits of a useful
medical product." Therefore, FDA is looking into injunctive actions against companies
that fail to provide the necessary pediatric information. Violation of an injunctive action
could result in the manufacturer being fined (Proposed Rule Section V.G (1)).
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What legal authority would FDA have over enforcing this proposal? The proposal cites
provisions that apply to FDA's authority over enforcing this proposal. For example,
FDA has authority to classify a drug as misbranded if the label is false or misleading,
dangerous to health when prescribed, recommended, or suggested in its labeling, or fails
to provide adequate directions for each intended use. There are other legal reasons
cited in Section VI of the regulations. Still, industry questions whether FDA has any
legal authority over forcing manufucturers to provide this data (2).

Analysis of Impact
An assessment of the impact of the proposed regulation is difficult to ascertain. The

FDA has estimated the number of additional studies and the cost that would have
accrued had these regulations been in place over the period 1991-1995. The drugs
approved over this period were categorized according to their potential use in the
pediatric population. The drugs were divided into 3 categories: 1) therapeutically
important, 2) other approvals, and 3) all other approvals. The "therapeutically
important" drug category was composed of those drugs that would have a potential use
in the pediatric population. The "other approval" category comprised drugs that would
have a potential to be used extensively in the pediatric population. The final category,
"all other approvals", consisted of drugs that would not be used for a pediatric patient.
This data was tabulated in Table 2. Of the 142 drugs approved, 60 (42%) were
estimated to have pediatric use and 82 (58%) did not. To estimate the additional studies
that would be required to provide adequate data, FDA assumed that much of the data
could be extrapolated from previous studies. Therefore, the 60 drugs that required
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pediatric information were further sub-divided into 3 groups according to the amount of
additional work required. The first of these 3 groups consisted of30 drugs that would
have required the least amount of new data; 23 drugs that already had some pediatric
labeling information and 7 drugs that already had ongoing pediatric studies at the time of
approval. Of these 30 drugs, FDA estimated that 15 would need limited additional data
in the form ofa study with approximately 50 patients. Of the remaining 30, 23 of the
drugs would have needed additional studies with approximately I 00 patients, and 7
drugs would have required extensive safety and effectiveness involving 300 patients.
Therefore, if these regulations had been in effect, the manufacturers would have needed
additional studies for 45 of the 60 drugs. This would have involved 5, 150 patients
(I 5·50+23· 100+7·300) or clinical trials of9 drugs involving 1,030 patients per year. In
addition, FDA is also authorized to request additional data for already marketed
compounds. FDA estimated two additional already marketed drugs per year into their
assessment. FDA further estimated that these additional 2 drugs require an additional
400 patients. Thus, totaling NMEs and already marketed drugs, there are 11 drugs and
1,430 patients per year. FDA has also noted that not all compounds will be approved.
To account for the additional pediatric studies that will occur for drugs that will not
ultimately be approved, FDA has further padded the numbers by increasing the estimate
by 30%, or 14 drugs and 1,850 pediatric patients per year (Proposed Rule Section X.B
(I)).

Costs of studies vary proportionately with the complexity of the clinical trial. FDA hired
a private consulting firm to estimate the costs of Phase IV trials. The firm estimates that
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for a fever or vaccine trial, the cost would range from $300-$500 per patient, for renal
disease the cost would be $3600 per patient, and for epilepsy the cost would be $5,000
per patient. Many researchers estimate $1 ,500-$3,400 per patient as an average cost.
To include all costs incurred during a study, FDA has estimated the cost to be $5,000$9,000 per patient. Based on this estimate, the annual cost to conduct the additional
studies for the 1,850 patients in any given year would have cost the industry $9 .25
million-$16.65 million per year. This estimate does not include any additional
expenditure for the manufacturing of the pediatric formulation . FDA estimates that the
cost of the additional formulations will not cost more than $1 million per year for each
drug (estimating that a total of 4 drugs per year will need additional formulations
bringing the total to $4 million for additional formulations) . There will also be additional
paperwork due to the increased regulations and FDA estimates these costs at $220,000
per year. The total estimation comes in at $13.5 million - $20.9 million per year
(Proposed Rule Section X.C.(l)). Delays in the submittal ofa NDA might result in a
further potential impact for the manufucturer due to extended drug development
time lines. These estimates do not include additional staff that will be needed by FDA to
process the supplements to already existing NDAs, increases in the number of studies
included in future NDAs, and the additional meetings being held during the development
process to ensure adequate pediatric trials (2).

Benefits of Regulations
These regulations address providing adequate dosing information in the label for
pediatric age groups. This information will be used to avoid adverse drug reactions and
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undertreatment in this population. Additionally, the information should increase the
availability ofnewer medications to the pediatric population. FDA compiled a list of the
top 25 NME's responsible for the highest number of adverse events in pediatric patients.
Eight (8) of these NME's had no pediatric labeling information (1 ,273 adverse events)
and 5 lacked label information for children under 12 (434 adverse events). Out of these
13 NME's, 11 would have been required to submit further pediatric labeling information
under these proposed regulations (Proposed Rule Section X.E.(1 )).

DISCUSSION
What will these proposals mean for industry? Obviously, there will be more initial cost
for manufacturers in that will need to run more clinical studies and create new pediatric
formulations. What about compounds that are off patent or are unpatentable drugs?
What sort of incentive is there for companies to spend additional resources on drugs that
they no longer have patent protection? Some of the smaller manufacturers will simply
not be able to fund these additional requirements. It is argued that the FDA estimates of
the cost of additional studies and the creation of new formulations are far too low.
PhRMA believes that there could be potential delays in drug development time and NDA
approvals. Additionally, the issue oflegal consent will be hotly disputed. Will parental
consent be considered enough? Industry is concerned that children recruited in these
studies will possibly be injured and subsequently sue for unlawful consent (2).

PhRMA has suggested that FDA follow European countries, Canada, and Japan when
looking to create additional regulations regarding pediatric clinical trials. In Europe,
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pediatric studies begin after the completion of Phase III trials and their age groups are
different from those assigned by FDA. Canada tests drugs in children after safety and
efficacy has been determined in the adult population. Japan excludes children from
Phase I and II trials and conducts trial in neonates and infants only after older children
have been studied (2).

Clearly, there is much debate over whether these regulations should be passed, by FDA
and industry, as well as health care providers and parents. There is a need for further
discussion on this matter both from the viewpoint of the child and also the realistic
requirements that can be placed on the pharmaceutical industry. It has been
recommended that a committee be formed, comprised of these individuals, to address
these many difficult questions. Until then, there are too many unresolved issues to
proceed with further implementation of the current proposed regulations as they stand.

19

REFERENCES

(1)

U.S. Department ofHealth and Human Services, Food and Drug Administration,

and Center for Drug Evaluation (CDER). Regulations Requiring Manufacturers to
Assess the Safety and Effectiveness ofNew Drugs and Biological Products in Pediatric
Patients. Docket No. 97N-0165. 08-01-1997.
http://www.fda.gov/cder/guidance/pedrule.htm. Date accessed 02-24-1 998.

(2)

Pharmaceutical Research and Manufacturers of America. PhRMA Letter to FDA

Regarding Docket No. 97N-0165 Pediatric Patients; Regulations Requiring
Manufacturers To Assess the Safety and Effectiveness of New Drugs and Biologic
Products; Proposed Rule. 13 Nov. 1997. http://www.phrma.org/sqmb/pediatric.html.

Date accessed 02-25-1998.

20

Table 1 Listing of Top 10 Out-patient Prescribed Drugs in Pediatric Patients
DRUG

INDICATION

1. Albuterol

asthma

#OF
PRESCRIPTIONS
1,626,000 under
12

2. Phenergan allergic
reactions

663,000 under 2

3. Ampicillin

infections

639,000 under 12

4. Auralgan

ear pain

600,000 under 16

5. Lotrisone

topical
infections

325,000 under 12

6. Prozac

depression and 349,000 under 16
OCD
_Q ,000 under !l
109,000 under 2
asthma
aerosol 399,000
under 5
248,000 under 16
d~ession
attention deficit 226,000 under 6
disorders,
narcolepsy
184,000 under 6
asthma

7. Intal

8. Zoloft
9. Ritalin

10. Alupent

Total

PhRMA Comments
Inhalation solution 2
strengths for ages 2+,
aerosol for children age
4+.
Label includes relevant
information in various
subsections.
No label information,
however physicians have
dosin_g_ knowled_g_e.
Grandfather clause - no
NOA on file (marketed
for over 40 years).
Statement in label not to
use in diaper dermatitis
due to harmful
concentrations in infants
and young children.
Studies nearing
com_.E!etion.
Solution in age 2+ and
metered dose inhaler for
age 5+.
Pediatrics use 10197.
Evaluation for under 6
years of age in process.
Revised label 2/97 for
dose age 6 and over and
one dose for 12 and
older.

over 5 million ':i!?ar

Abbreviations: OCD=obsessive compulsive disorder, PhRMA= Pharmaceutical
Research and Manufacturers of America, NDA=new drug application
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Table2
Pediatric Labeling ofNME's and Biological Products Approved 1991-1995
with Potential Pediatric Use

#NMEs

% of All
A_£E!"OVed
33

% Some Pediatric
Labelin__g_
34 % (16/47)

% No Pediatric
Information
66 % (31 /47)

Some
47
Potential
Pediatric Use
Wide
13
54 % (7/13)
46 % (6/13)
9
Pediatric Use
Total
42
60
38 % _{_23/6Ql
62% _JJ7/6Ql
#Of the 142 NME and B10log1cal Products approved m this penod, 60 were deemed to
have potential use in the pediatric population.
Abbreviations: NME=new molecular entity
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MANUSCRIPT II

Population Phannacokinetics of Azithromycin in the Pediatric Population

ABSTRACT
A population pharmacokinetic analysis was conducted for azithromycin on data from
pediatric patients enrolled in four separate clinical trials. The data, which consisted of
526 serum concentrations from 58 patients administered one to five daily oral doses of
azithromycin ranging from 5 mg/kg to 12 mg/kg per day, was analyzed in NONMEM. A
two compartment model with parallel zero-order and first-order absorption was found to
best fit the data. Potential covariates were assessed for oral clearance (CL/F), oral
volume of distribution in the peripheral compartment (V2/F), intercompartmental oral
clearance (Q/F), and the first-order absorption rate constant (ka). Models were initially
developed using the first order (FO) method and subsequently refined using the first
order conditional estimation (FOCE) method. Weight was found to be a significant
covariate for both CL/F and V2/F. Neither age, gender, the presence of anemia, cancer,
pneumonia, nausea, colitis, nor the concomitant usage of albuterol, amikacin, captopril,
ceftazidime, ceftriaxone, digoxin, diphenhydramine, dopamine, fentanyl, furosemide,
midazolarn, morphine, nystatin, ranitidine, sulfamethotrexate, ticarcillin, nor vancomycin
appeared significant for any pharmacokinetic parameter.
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INTRODUCTION
Azithromycin is an azalide antibiotic (a subset of macrolide antibiotics), is active against a
wide spectrum of microorganisms, and bas a low side effect profile ( 1-4). Azithromycin is
indicated for pediatric usage for the treatment of acute otitis media, community-acquired
pneumonia, and pharyngitis/tonsillitis (5). Following administration, azithromycin
undergoes extensive and rapid distribution in tissue. Thereafter, distribution from tissue is
the rate limiting process for elimination of azithromycin, thus leading to a long terminal
half-life (around 55-70 hours for both adult and pediatric populations) (1 ;2;4-6). Because
of these properties, azithromycin is administered once daily and for a shorter duration
than other macrolide antibiotics ( 1;2;7-10). Appendix I provides a more extensive
overview of the pharmacokinetics of azithromycin.

Clinical trials have been conducted in pediatric patients to determine the
pharmacodynarnic and pharmacokinetic characteristics in this group compared to the
adult population (9-11 ). These studies, and other safety clinical trials, showed that once
daily dosing was well tolerated and efficacious in pediatric patients (7-12). Results from
two of these studies have been used for the development of dosing guidelines in
pediatrics (5;10;1 l). Current recommended dosages for pediatric patients are
determined by indication. For the indications of otitis media and community-acquired
pneumonia, pediatric recommendations are for I 0 mg/kg on day 1 and 5 mg/kg doses on
days 2-5. A higher dose of 12 mg/kg for days 1-5 is recommended for children with
pharyngitis/tonsillitis (5). In contrast, a 500 mg single dose given on day 1, followed by
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250 mg single doses on days 2-5 is recommended for adults with these indications
(5;13).

After a single oral dose of 500 mg azithromycin in an adult population, the following
pharmacokinetic parameters have been reported: peak serum concentration (Cmax) of
around 0.4 mg/L, time to peak concentration (Tmax) of2.5 hours, area under the
concentration time curve from 0-24 hours (AUCo-2•) of2.36-2.60 µg·hr/mL, steady state
volume of distribution of23-3 l Ukg, clearance of9 mL/min/kg (0.54 L/hr/kg), and
bioavailability of37% (no standard deviations were provided with these results)
(I ;2;4;5;13-15). When azithromycin was administered to children 0-5 years of age (I 0
mg/kg day I; 5 mg/kg days 2-5), Cmax was 0.224 +/- 0.120 µg/ml, Tmax was 1.8 +/0.4 hours, and AUCo-24 was 1.842 +/- 0.651 µg ·hr/mL. Ln a different study, when
azithromycin was administered at the same dose to children 6-15 years of age (I 0 mg/kg
day I ; 5 mg/kg days 2-5), Cmax was 0.383 +/- 0.142 µg/mL , Trnax was 2.4 +/- I. I
hours, and AUCo-24 was 3.109 +/- 1.033 µg·hr/mL (5;10;1 l). Comparing these two
studies, children 0-5 years old versus children 6-15 years old have significantly lower
Cmax and AUC values while their oral clearance is significantly higher (9;11). Thus, it is
proposed that age may prove to he an important covariate for oral clearance. The
coefficient of variation for oral clearance (CL/F=4.83 L/hr/kg) in a different pediatric
study was reported to he 74%, but the cause of the variability was not identified (9).
Otitis media and pharyngitis are very common infections, especially in the younger
pediatric population (8; 12) and an understanding of the contribution ofage or other
factors that may explain interpatient variability in clearance may prove beneficial. The
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lack of information on variability may be addressed by utilizing nonlinear mixed effects
modeling (i.e. population pharmacokinetic models) for azithromycin in the pediatric
population.

Nonlinear mixed effects modeling permits the use of sparse data (2 or more plasma
concentration samples not necessarily from the same dosing interval per patient) from a
large number ofrepresentative patients in the population ( 16-18). The population
method pools all data collected and calculates population pharmacokinetic parameters
(e.g. CL/F). Additionally the focus of the analysis is on the source and correlation of
variability in pharmacokinetic parameters among individuals in the population (19) .
Thus, population pharmacokinetics focuses on the study population (unit of analysis)
initially and moves out to the individual. Population analyses also provide quantitative
estimates of both the interindividual and intraindividual (i.e. residual) variabilities of the
population (l 7;18). lnterindividual variability may be accounted for by adding specific
patient characteristics (e.g. demographic information, concomitant medication usage,
etc.) into the population model. Patient characteristics that cause changes in the doseconcentration relationship can be identified, assessed, and then appropriate dosing
modifications can be determined to enhance efficacy or to reduce the chance ofadverse
events (16;17).

The purpose of this investigation was to evaluate whether a population pharmacokinetic
modeling approach could be used to develop a model for data combined from four
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pediatric trials and to determine if any patient characteristics could be identified that
might provide useful information when selecting a dose of azithromycin in children.

METHODS AND MATERIALS

Patients. Plasma concentration-time data were obtained from pediatric patients enrolled
in four Phase 1 clinical studies (see Table 1). These four clinical trials were conducted to
evaluate safety, efficacy, and pharmacokinetics after oral administration ofazithromycin
in pediatric patients. Results for three of the four studies (Protocols 054, 136, and 172)
have been reported elsewhere (9-11 ). The fourth study (Protocol 043) was terminated
early due to difficulties with patient enrollment. Protocol 043, 054, 136, and 172 were
conducted during 1993, 1993, 1991, and 1992-1993 respectively. The appropriate
institutional review boards approved all protocols. The patient's parent or a legal
guardian gave written informed consent prior to inclusion in the study.

This retrospective combined data analysis was conducted on all pediatric patients with
measurable azithromycin concentration-time data collected in the four Phase I clinical
trials. A random selection of20% of the patients from the combined dataset was
reserved to assess the predictive performance of the model, i.e. internal validation of the

final model. The data from the remaining 80% of the patients was used for the model
development. Two patients in Protocol 054 (I male 2 year old weighting l 3kg and
concomitantly medicated with captopril, furosemide, and morphine; I male I year old
weighting 9kg with colitis and concomitantly medicated with captopril, digoxin,
diphenhydramine, dopamine, fentanyl, furosemide, morphine, and nystatin) were
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excluded from the combined data analysis because they had no measurable azithromycin
concentration levels at any time point. Thus, there were a total of 58 pediatric patients
used for the combined data analysis: 46 were included in the model development dataset
and 12 were included in the validation dataset. Characteristics of the pediatric patients
included in the dataset are presented in Table 2.

Azithromycin administration. Azithromycin (oral suspension) was used for dosing for
each clinical trial as instructed in each of the four protocols. In Protocol 043, a single
daily dose of azithromycfu (12 mg/kg) was administered on days 1-5. In Protocol 054, a
single daily dose of azithromycin ( 12 mg/kg) was administered on day I. Pediatric
patients that were enrolled in the multiple dose portion of the clinical trial also received
single daily doses of azithromycin ( 12 mg/kg) administered on days 2-5 (9). In Protocols
136 and 172, a single daily dose ofazithromycin (10 mg/kg) was administered on day 1
and single daily doses of 5 mg/kg on days 2-5 ( 1O;I I). For Protocols 043, 054 and 136,
azithromycin powder was reconstituted to I 00 ml volwne to yield 40 mg/ml
azithromycin concentration (9;10). For Protocol 172, azithromycin was provided in a 20
mg/ml suspension (11). Azithromycin was dosed in the morning either one hour before
or two hours after the morning meal (9-11 ). In Protocols 043 , 136 and 172, patients
fasted overnight before receiving their final dose on day 5 (10;1 I)

Blood Collection and Sample Analysis. For Protocol 043 , serwn samples were
collected at 0 (just prior to dosing), 0.5 , I, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 144
hours post dose on day 5. In Protocol 054, serum samples were collected at 0 (just prior
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to dosing), I, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours post dose on day I. For
patients enrolled in the multiple dosing portion of the trial, additional samples were
collected at I , 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post dose on day 5 (9). For
Protocols 136 and 172, serum samples were collected at 0 (just prior to dosing), 0.5, I,
2, 4, 6, 8, 12, 24, 48, and 72 hours post dose on day 5 (IO; 11 ). Concentrations of
azithromycin in the serum samples, for all of the protocols, were determined by a highperformance liquid chromatography-mass spectrometry method as published elsewhere
(9-1 1;20).

There were a total of 526 concentration values used in the model development dataset
and 148 concentration values in the validation dataset. No steady state assumptions were
made with any concentration values.

Data Preparation and Phannacokinetic Analysis. Demographic, plasma collection
time, medical history, concomitant medication, concentration, dosing history, physical
examination, and adverse event data relevant to the pharmacokinetic analysis were
extracted from raw data sources and merged using SAS v6. l 2 on a V AXNMS
mainframe (Digital Equipment Corporation, Maynard, MA.). Twenty percent (20%) of
patients from each protocol were then randomly removed from the model building
dataset to form the validation dataset. The remaining 80% of the data was used for the
model development dataset. The pbarmacokinetic analysis was performed using
NONiinear Mixed Effect Model (NONMEM) version 5 level I. I double precision on a
Pentium III computer with a Visual Fortran 5.0 compiler (21-25).
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Data Analysis Strategy.
An approach proposed by Mandema, et. al. ( 1992) was used for the data analysis: 1) a

base model was developed for the population, 2) the estimates found during step I were
used to explore potential covariates with the base model, and 3) a mixed effects model
was developed to describe the relationship between the covariates and pbarmacokinetic
parameters (26). 1n this analysis, forward addition ofcovariates was used to generate
the full model, while a backwards elimination approach from the full model was used to
determine the final model.

Pharmacokinetic and statistical models were evaluated to determine the model that best
described the model development dataset (n=46 patients). To discriminate between
models, the following criteria were used: 1) a decrease in the objective function value
(which is proportional to minus twice the log-likelihood of the data) of3.84

<i

distribution, df=l , p< 0.05) or greater following the addition ofa single parameter was
deemed statistically significant; 2) diagnostic plots (e.g. predicted concentration versus
observed concentration data, predicted concentrations overlaying all concentration data
versus time, weighted residuals versus predicted concentration values), 3) minimiz.ation
of variances: reduction ofinterindividual variances and residual variability, and 4) the
Akaike Information Criterion (AIC) (16;21;26;27).

Phannacokinetic Model. To compare adult and pediatric models and estimates, a
population model was initially developed using data from a traditional pbarmacokinetic
study conducted in healthy normal adult male subjects (age=27-54 years, weight=63-90
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kg) (28). The subjects had no evidence of a history of disease, were taking no
concomitant medications, and were emolled in a study to evaluate azithromycin
phannacokinetics after single oral and intravenous doses. An intensive blood sampling
regimen was used. A total of twelve subjects started the study but only ten completed
both anns of the study. Two subjects dropped out after the first arm (one subject in each
cohort), leaving eleven subjects that completed each arm. The eleven subjects from the
oral azithromycin administration cohort contributed 120 concentration records to the
modeling dataset; blood samples were collected at 0 Gust prior to dosing), 0.5, I, 2, 3, 4,
6, 8, 12, 24, 48, and 72 hours post dose on day I. Several pharrnacokinetic models were
evaluated to fit the adult data: one-compartment and two-compartment models with
zero-order, first-order, and a combination zero- and first-order absorption. A twocompartment model with a combination parallel zero-order and first-order absorption
best described the data. The two-compartment model with both absorption terms was
parameterized as oral clearance (CL/F), oral volume of distribution in the central
compartment (V l/F), oral volume of distribution in the peripheral compartment (V2/F),
intercompartmental oral clearance (Q/F), the first-order absorption rate constant (ka),
and the zero-order rate constant (R) (NONMEM subroutines ADV AN4 TRANS4).

As with the adult dataset, several pharmacokinetic models were used to evaluate the
pediatric data: one, two, and three compartment models with zero-, first- , and
combination parallel zero-and first-order absorption terms (14;29;30). For these models,
the final parameter estimates from the adult model were used as the initial estimates for
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the modeling of the pediatric data The two compartment model with parallel zero- and
first-order absorption rates best fit the pediatric data and was used as the base model.

Statistical Model An additive, proportional, and exponential-error model were
evaluated for interindividual variability of the pharrnacokinetic parameters (23;3 l). For
example:
Additive model: 0i=TV0 + T\i.0
Proportional model: 0i=TV0-(I + Tt;,9 )
Exponential model: 0i=TV0·EXP(Tt;.0)

2
where T\i.9 is a random variable distributed with a zero mean and variance of ro 9 and

TV® is the population mean value for 0.

Residual variability was modeled using a proportional-error model and an additive and
proportional error model (23;3 1):
Proportional model: C;i=Cp<e<1.;j' (l+&;j)
Additive and Proportional model: Cu=C,..,,,;r (I +Enj) +

Ei;;

where C;i is the observed serum concentration value for the jth individual at time=i,
C,..,,,;i is the model predicted serum concentration for the jth individual at time=i, and Enj
and E2 ;i are randomly distributed variables with a zero mean and variance of cr2 •
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Analysis of Covariates. Once the base pharmacokinetic model was obtained, the
posthoc Bayesian estimation (first order (FO) method) was implemented to obtain the
individual parameter estimates to evaluate potential influences of covariates. An
exponential error model for interindividual variability and a proportional error model for
the residual variability were initially assumed for the covariate analysis. For each
pharmacokinetic parameter, the potential influence of covariates on the individual
pharrnacokinetic parameter estimates was evaluated. This evaluation was performed
using stepwise linear regression in S-Plus version 4.5. For each pharrnacokinetic
parameter, covariates were added and removed from the model in an iterative process
based on a covariate' s calculated residual sum of squares and the AIC. The covariate
with the largest reduction in the AIC was then added or dropped from the model. The
stepwise iterations stopped when no additional step decreased the AIC (32). Diagnostic
plots were also used to screen for the potential influence of covariates on the
pharrnacokinetic parameters (i.e. covariate versus individual pharrnacokinetic parameter
estimate). Age and weight were treated as continuous variables. Gender was treated as
an indicator variable (O=fernale, !=male). The presence of asthma, anemia, cancer,
pneumonia, nausea, colitis, albuterol, arnikacin, captopril, ceftazidirne, ceftriaxone,
digoxin, diphenhydrarnine, dopamine, fentanyl, furosernide, rnidazolarn, morphine,
nystatin, ranitidine, sulfamethotrexate, ticarcillin, or vancomycin at any point in the study
was represented as an indicator variable (O=no, I =yes). Any concomitant medication,
adverse event, or disease status in fewer than four of the patients was not tested.
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Covariates that were found to be statistically significant from the initial screening in SPlus were then evaluated in the base model using NONMEM . Each covariate was added
one at a time into the base model. Covariates were deemed as statistically significant in
NONMEM as outlined above; i.e. a change of >3.84 in the objective function value,
diagnostic plots, reductions in variability, and the AIC (I 6;21 ;26;27). A large number of
covariates were found to be statistically significant in both S-Plus and NONMEM.
Because of the number of significant variables, the model development was done in a
forward stepwise manner, in a manner similar to that published by Lee et. al.(33).

To generate the model in a forward stepwise manner, the change in the objective
function value was used as the initial criteria for a covariate' s inclusion into the model.
The list of covariates that generated a change in the objective function value of greater
than 3.84 for any pharmacokinetic parameter was sorted in descending order. The 95%
confidence interval was calculated for the covariate parameter estimate that generated
the largest change in the objective function value. If the 95% confidence interval did not
include the null value, this parameter was then added to the base model. If the 95%
confidence interval did include the null value, the parameter was not added and the
covariate that generated the next largest change in the objective function value was then
evaluated. Once the initial covariate was identified, the other covariates in the list
(whose change in objective function value were greater than or equal to 3.84) were
added individually. Any covariate that did not generate a further change in the objective
function value of3.84 or greater in this second run was discarded from the model
building process. Again, the covariates were sorted by magnitude of the change in the
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objective function value. The top covariate whose 95% confidence interval did not
include the null value then became the second covariate to be added to the model. This
process continued until there were no more covariates whose addition into the model
would generate an objective function value change of greater than 3.84 and whose
parameter estimate value would not include the null value, thus the full model was
created. A backward elimination procedure was then performed on the full model. Each
covariate was removed one at a time from the full model. If the objective function value
increased by a more conservative value of7.88

<i distribution, df-=l, p< 0.005), the

parameter was included in the final model.

The next step in the analysis was the validation of the model. Model validation was
performed by fixing all parameter estimates (both fixed and random effects) to their final
model value. The model was then run using the validation dataset (20% of the total
data). The posthoc Bayesian estimation (POSTHOC option on $ESTIMATION) was
invoked and the residuals calculated in $ERROR were saved in the $TABLE command.
The data output from NONMEM was then exported to Microsoft Excel (version 98).
Bias (mean prediction error) and precision (root mean square error) of the predicted
concentration values were calculated to describe the predictive performance of the model
(33-35):

I

N

precision= - _L(pei) 2
N ,. ,
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I

N

bias=- ~:>e1
N ,_,

where pe;= the difference between the ith measured and predicted azithromycin
concentration value at a given time and N=the number of pairs of predicted and observed
azithromycin concentrations. Ideally, a value of zero is desired for both precision and
bias; the smaller the magnitude of the residual, the lower the magnitude of the value of
precision and bias (35). The 95% confidence intervals of precision and bias were also
calculated by using the following equation (33-35):

x., ± lo.97l, N -

I .

SE(X..)

As another form of validation, the NONMEM analysis using the final model was
conducted on I 00% of the data. The estimates of the pharmacok:inetic and statistical
parameters were compared to those obtained with the development of the final model
dataset (80% of the data) (16;36;37).

Finally, the analysis was performed using the first order conditional estimation (FOCE)
method using 100% of the data (17;22;38). Backwards elimination was performed on
the final model obtained with the FO method to determine covariate signilicance. The
FOCE estimates of the phannacok:inetic parameters, estimates of the statistical
parameters, and diagnostic plots were compared with the final FO model using 100% of
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the pediatric data. Bias and precision of the predicted concentration values were
calculated to descnbe the predictive performance of the FOCE model.

RESULTS
Adult Phannacokinetics:
The adult dataset was best described by using a two-compartment model with a zeroorder rate of absorption. For the adult model, interindividual variability was described
with an exponential error term on CUF. The base model equations, parameter
estimates, percent relative standard error (%RSE), and 95% confidence intervals for the
adult dataset are given in Table 3 (mean weight=73.6 kg). A previous study modeled a
similar dataset using a two-compartment model with zero-order absorption (14). The
previous study found that a zero-order absorption rate was a superior fit for the data
when compared to a first-order absorption rate model. The pharmacokinetic parameter
values reported from the previous study were similar in values for oral clearance and oral
volume of distribution to this analysis.

Pediatric Phannacokinetics (FO Method) for Base Model- 80% data:
In contrast with the adult data, a two-compartment model with zero- and first- order
absorption rate constants best fit the pediatric model development dataset. The
parameter estimates calculated from the adult model were used as the initial estimates for
the pediatric model development dataset. During model development, interindividual
error terms on CL/F, V2/F, ka, and Q/F significantly improved the model, i.e. a decrease
in the objective function of3.84

Ci distribution, df=I , p< 0.05) .
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lnterindividual error

terms on Vl/F and R did not significantly improve the fit of the model and were
excluded from further model development. Interindividual variability was best described
by an exponential error model. Residual variability was best described by using a
proportional error model. The base model equations, parameter estimates, percent
relative standard error (%RSE), and 95% confidence intervals for the pediatric dataset
are given in Table 4 (mean weight=26.5kg). When standardized by the mean weight, the
parameter values generally compare well for the pediatric and adult populations (see
Table 5), although the estimate for V2/F in the pediatric population was approximately
double that of the adult population. The observed serum concentration versus predicted
serum concentration values, residual versus predicted serum concentration values, and
weighted residual versus predicted serum concentration values are plotted in Figures 1-3
respectively. In Figure I , for larger concentration values, there is a larger spread seen in
the data There is a trend seen in the residual versus predicted serum concentration plot;
the larger the value of concentration, the more negative the residual (Figure 2). This
trend does not appear to be corrected by weighting the residual; smaller values of
predicted serum concentrations now have larger variability (Figure 3).

Individual covariate testing (FO Method) for Full/Final Model - 80% data:
A summary of the forward stepwise model development for inclusion of covariates for
pharmacokinetic parameters is provided in Table 6. The full model consisted of albuterol
and weight as covariates for CL/F, ceftriaxone and weight as covariates for V2/F,
dopamine as a covariate for Q/F, and morphine as a covariate for ka (Table 7).
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Backwards elimination was then performed to generate the final model. Each covariate
was removed individually from th.e model. A covariate was retained in the final model if
there was a significant decrease in the goodness of fit (i.e., objective function value
decreased by 7.88

Ci distnlmtion, df=I, p< 0.005).

Following the backwards

elimination procedure, only albuterol and weight were identified as significant covariates
for CUF and only ceftriaxone and weight for V2/F. Additionally, the parameter ro2V2/F
was removed from the model since its 95% confidence interval included the null value.
The final model equations, parameter estimates, percent relative standard error (%RSE),
and 95% confidence intervals are given in Table 8. The diagnostic plots ofCL/F versus
weight, CUF versus albuterol, V2/F versus weight, and V2/F versus ceftriaxone for the
base model parameter estimates are shown in Figures 4-7 respectively. For the figures of

CUF and V2/F versus weight (Figures 4 and 6), the regression line has a positive slope;
indicating as weight increases, so does the value of the pharmacokinetic parameter. For
the albuterol and ceftriaxone plots (Figures 5 and 7), the box plots show the spread of
the pharmacokinetic parameter values. The confidence intervals for the use of the
concomitant medication overlap each other on both figures, indicating that there may not
be any difference between the two groups. There are lower values for %RSE seen with
0 values (10.6-24.3%) than the variability parameters, ro 2 and

%RSE for Vl/F, Q/F,

ro

2
cUF.

ro2.., and cr

2

cl (20.0-44. l %).

The

are lower for the final model as compared to

the base model (12.7 vs. 14.2, 10.6 vs. 12.9, 39.5 vs. 43.2. 36.3 vs. 42.0. and 20.0 vs.
24.9 respectively). The %RSE for ka, R, and ro 2<YF are higher for the final model as
compared to the base model (15.5 vs. 14.5, 14.6 vs. 11.1 , and 44. l vs. 39.6
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respectively). Parameter estimate ranges are as follows: CUF=7-363 Uh, V2/F=9004387 L, Q/F= l4-246 Lfh, and ka=0.2-19.l Uh.

Validation dataset (FO Method) - 20% data:
The predicted performance of the validation dataset is shown in Table 9 . There are both
bias and imprecision in the model between the observed and predicted azithromycin
concentrations as shown with the 95% confidence intervals not including the null value.
The observed serum concentration versus predicted serum concentration values and
weighted residual versus predicted serum concentration values plots are shown in
Figures 8 and 9 respectively. In Figure 8, it appears that the model still had difficulty
estimating the larger concentration values. ln Figure 9, larger weighted residuals are
seen for a few smaller predicted concentration values.

Final Model (FO Method) - 100% data:
The final model equations, pharrnacokinetic and statistical parameter estimates, percent
relative standard error (%RSE), and 95% confidence intervals generated using I 00% of
the data are shown in Table I 0. The diagnostic plots of observed versus predicted serum
concentration values, observed versus individual predicted serum concentration values,
residuals versus predicted concentration values, and weighted residuals versus predicted
serum concentration values are depicted in Figures I 0-13. Figures I 0, 11 and 12 show
that the model fails to adequately predict large concentration values. Figure 13 shows
that the weighted residuals are not biased, that is, there is a scatter of weighted residual
values over the entire predicted concentration range. When I 00% of the pediatric data
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was used, weight and albuterol were retained as covariates for CL/F and weight and
ceftriaxone for V2/F.

Final Model (FOCE Method) - 100% data:
The final model equations, pharmacokinetic and statistical parameter estimates, percent
relative standard error (%RSE), and 95% confidence intervals generated using the FOCE
method on 100% of the data are shown in Table I I . When the final model from the FO
method was evaluated using the FOCE method, albuterol and ceftriaxone were no longer
statistically significant covariates. lnterindividual variability was best described by an
exponential error model on CLIF and ka. Residual variability was best described by
using a proportional error model. The diagnostic plots of observed versus predicted
serum concentration values, observed versus individual predicted serum concentration
values, residuals versus individual predicted serum concentration values, and weighted
residuals versus individual predicted serum concentration values are depicted in Figures
I 4- I 7. Figures 14 and IS show that the FOCE model better describes the dataset.
There was a more uniform distribution of data points spread over the line of identity.
Figure 16 shows that the residual plots do not differ much between the two models.
Figure I 7 shows that the weighted residuals are biased for smaller predicted
concentration values. When 100% of the pediatric data was used with the FOCE
method, weight remained as a covariate for CUF and V2/F in the final model.
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Validation dataset (FOCE Method) - 20% data:
The predicted performance of the validation dataset is shown in Table 12, where it can
be observed that bias and imprecision were present between the observed and predicted
azithromycin concentrations: the 95% confidence intervals did not include the null value.
The values for precision and bias are similar to the values obtained using the FO method.
The observed serum concentration versus predicted serum concentration values and
weighted residual versus predicted serum concentration values plots are shown in
Figures 18-19 respectively. In Figure 18, the model still had difficulty estimating the
higher concentration values. In Figure 19, larger weighted residuals are seen for a few
smaller predicted concentration values. Figure 20 shows the overall fit of the model by
comparing predicted and observed concentration values versus time. At the later time
points, the model consistently overpredicts the concentration values.

Model parameters versus published results:
A further validation of the population analysis can be found by comparing the individual
study pharmacokinetic results with a prior published analysis. For the 054 study, oral
clearance and V l /F were reported. There were 23 evaluable patients in the analysis
resulting in values ofCUF=4.83 +/- 3.59 L/h/kg (CV=74%) and Vl/F=3 8.1 L/kg (range
of9.6-l 84.6 L/kg - standard deviation and CV were not provided) (9). The FOCE
analysis on 100% of the pediatric dataset gave the following estimates of parameters:
CL/F(%CV) (L/h) = 18.2(31.3) + 2.25(14.3)-weight(kg). Using the mean weight for
the population (26.5 kg), the value for CUF was 2.93 L/h/kg. For the 100% pediatric
dataset FOCE analysis, the value for Vl/F was 5. 1 (L/kg). While the value for CL/F
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compares favorably between the two analyses, the value for Vl/F in our analysis appears
substantially smaller than the prior analysis.

DISCUSSION
The study demonstrated that a population pharmacokinetic modeling approach could be
used to model azithromycin concentration-time data from four pediatric clinical trials.
Additionally, the study demonstrated that it was possible to identify covariates to explain
variability in the pharmacokinetic parameters. When the FOCE method was used,
weight was found to be a significant covariate for CUF and V2/F.

Weight was an anticipated covariate for both CL/F and V2/F and supports the current
dosing recommendations for azithromycin based on weight (5). Age has been proposed
as a potential significant covariate since a higher oral clearance has been seen in children
0-5 years of age as compared to children that are 6-15 years of age (9) . However, the
population analysis found that while age created a large difference in the objective
function value when added individually to the base model, the 95% confidence interval of
age's parameter estimate included the null value; age was not considered statistically
significant. Additionally, weight and age were highly correlated covariates. Therefore
age was not evaluated in further model development.

When the FO method was used in the analysis, two of the covariates identified as
significant subsequently become insignificant when the FOCE method was used.
Albuterol was identified as a statistically significant covariate for CUF and ceftriaxone
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for V2/F. Albuterol was given to 22% (13 out of 58) of the entire population, while
ceftriaxone was given to 14% (8 out of 58). No plausible explanation for these effects
could be found in the literature. However, it is interesting to note that many of the
patients taking albuterol and ceftriaxone were also taking many concomitant
medications. Additionally, all but one of the patients taking these medications were from
the 054 study. The patients in study 054 were different from the children in the other
three studies in that they received multiple concomitant medications and had more acute
and chronic illnesses (all children were hospitalized); 12 of the 26 patients were cancer
patients. Children in studies 043, 136, 172, and the non cancer patients in 054 were
enrolled in their respective protocols for otitis media or pharyngitis (9-11 ).
Consequently, all concomitant medications were taken by approximately half of the
patients in study 054 (12 out of58 patients, or 21%). Thus, this analysis may not have
had sufficient power to fully evaluate the interacting potential of many of these drugs.
When the FOCE method was used, both albuterol and ceftriaxone ceased to be
significant in the model.

A previous analysis found a large interpatient variability in the parameter estimates for
study 054 (9). In this study analysis, there were statistical differences (p<0.0001) in oral
clearance in children <=5 years old (CL/F=4.27 Uhr/kg) compared to the group of
children 6 years of age (2.27 Uhr/kg) and greater. In contrast the present analysis did
not find age to be a statistically significant covariate for oral clearance.
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Model misspecification may have led to the poor fit of the model for large concentration
values. A two compartment model was found to best fit the data However, more recent
studies indicate that azithromycin follows three compartmental pharmacokinetics
(29;30). This could possibly explain the under-prediction of concentrations at later
times. In the previous analysis of study 054, a zero-order input was used to model drug
absorption (9). In the present study, the data was best fit using both zero order input
and simultaneous first order input. While the diagnostic plots and also the change in the
objective function value signaled a better fitting model when both inputs were used, the
plots still showed that there was bias and imprecision when calculating the predicted
concentration values with this model. Additionally, the bias and imprecision in the model
was seen with the results of the predictive performance using the validation dataset. In
Figure 20, the predicted concentration values were consistently larger than the observed
values. This finding would be indicative of a three compartment model being a
potentially better fit. Further work could be done evaluating a three compartment model
with various error models using the FOCE method.

Our models were generated using both FO and FOCE estimation methods in NONMEM.
The FO estimation method obtains values for

T]

values after the population parameter

estimates have been obtained. Therefore these estimates of T] are computed with the
assumption that the variance model is that of the mean individual. The FOCE method
does not use this assumption. The values of Tl are computed simultaneously with the
population estimates (l 7;22). While using the FOCE method, some of the imprecision in
the model was addressed, as seen in the improvement in the observed azithromycin
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serum concentration versus predicted azithromycin serum concentration plots.
However, the weighted residual plots showed an increase in bias for low concentration
values.

In conclusion, this study has shown that population pharmacokinetic models can be used
to model azithromycin serum concentration time data obtained after oral dosing in the
pediatric population. A two-compartment model with a parallel NONMEM calculated
zero-order and first order absorption rate constant was used to describe the
concentration versus time data for the pediatric data pooled across four clinical studies.
When using the FO method, weight and albuterol for CUF and weight and ceftriaxone
for V2fF were found to significantly decrease their respective parameter estimates.
When using the FOCE method, weight for both CL!F and V2fF was found to
significantly increase the value for their respective parameter estimates. The model using
the FOCE method best describes the dataset, though there was still bias in the final
model.
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Table I. Features of Pediatric Studies Included in the Population Phannacokinetic
Analysis of Azithromycin
Protocol
Number

Design

Azithromycin Oral
Dosage

043**

Open label, noncomparative,
non-randomized trial in patients
with Group A beta-hemolytic
streptococcal (GABHS)
pruUyngitis
Open label, noncomparative,
non-randomized trial to
characterize the disposition and
tolerance of azithromycin after
single and multiple oral doses
in patients with and without
cancer
Open label, noncomparative,
non-randomized trial in patients
with Group A beta-hemolytic
streptococcal (GABHS)

Single dose 12
mg/kg for days 1-5

054

136

Total Number of
Patients*
Gender and A_g_e
n=5
3 male; 2 female
2-12 years of
age

Single dose 12
mg/kg on day l;
single dose 12
mg/kg on days 2-5

n=26
15 male; 11
female
0-15 years of
age

Single dose I 0
mg/kg on day 1;
single dose 5 mg/kg
on days 2-5

n=14
5 male; 9 female
6-15 years of
age

Open label, noncomparative,
Single dose l 0
non-randomized trial in patients mg/kg on day I;
with acute otitis media
single dose 5 mg/kg

n=13
7 male;6 female
1-5 years of age

~tis

172

ond~2-5

* Number of patients m study with measurable concentrations of azJthromycm
** Protocol 043 was discontinued early due to poor study enrollment
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Table 2. Characteristics of Pediatric Patients Evaluated in the Population
Pharmacokinetic Analysis of Azithromycin
Validation dataset
Model develQJ>_ment dataset
46
12
26
7
20
5
s.ssJ:ran__g_e=0-1~
4.83J:ran~l-1~
26.5]!-an__g_e=4-8Ql
2s.2:Iran~7-8~
10
3
I
5
6
1
4
2
3
9
I
3
4
2
2
6
14
6
4
1
4
I
3
I
2
2
5
1
4
1
4
0
M~hine*
9
1
Nausea
N_l'.'tatin*
4
1
Pneumonia*
5
3
Ranitidine*
7
2
Sulfaroethotrexate•
4
2
Ticarcillin*
5
0
Vancom_y_cin*
10
4
• All of the children with these charactensttcs are from Protocol 054.
Characteristic
Total number of_.E.atients
Male
Female
A__g_eJr..ear&
We!g!it{kg}
Albuterol*
Amikacin*
Anemia*
Asthma
Cancer•
CaQtCJ]>_ril*
Ceftazidime*
Ceftriaxone•
Colitis
Digman•
Dyihenh_y_dramine*
DCJ]>_amine*
Fentan_.I!*
Furosemide*
Midazolam*
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Table 3. Base Model Equations, Parameter Estimates, Percent Relative Standard Errors
(%RSE), and 95% Confidence Intervals (Adult Dataset)

Parameters
CUF~

Vl/F (L)=02

_Q_IFJ.UhL e,
V21F(L}=®•
RJ_mJlZ!E ®s
2
C0 CLIF

cl

Estimated
Values
138
849
240
2990
215
0.229
0.291

%RSE
12.0
17.2
16.6
14.0
9.86
41.6
17.5

95% Confidence
Intervals
106,170
563,1140
162,318
2170,3810
173,257
0.042,0.416
0.191,0.391

Abbreviations: CUF = oral clearance, Vl/F = oral volume of distribution in the central
compartment, Q/F = intercompartmental oral clearance, V2/F = oral volume of
distribution in the peripheral compartment, R= zero-order absorption rate constant,
2
co cUF =interpatient variability ofCL/F, cl =variance of residual error.
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Table 4. Base Model Equations, Parameter Estimates, Percent Relative Standard Errors
(%RSE), and 95% Confidence Intervals (Pediatric Model Development Dataset (80% of
Data))- FO Method

Parameters
CL/F(Llh°"""FE>1
VJ!F(i}=02
QIF(i)h)= 03
V2/F(L):" e.

ka~e,
R~06
~CUF
~O/F
~V2/F
~ka
~

Estimated
Values
55.3
258
120
1900
1.86
89.6
0.600
0.245
0.353
2.450
0.215

%RSE
13.7
14.2
12.9
12.3
14.5
I I.I
43.2
39.6
39.7
42.0
24.9

95% Confidence
Intervals
40.5,70.1
186,330
90,150
1443,2357
1.33,2. 39
70,109
0.092, l.108
0.055 ,0.435
0.079,0.627
0.431 ,4.469
0.109,0.321

Abbreviations: FO=fust order, CUF = oral clearance, Vl/F =oral volume of distribution
in the central compartment, Q/F = intercompartmental oral clearance, V2/F = oral
vo lume of distribution in the peripheral compartment, ka= first-order absorption rate
constant, R= zero-order absorption rate constant, ro2cUF =interpatient variability of CL/F,
2
ro <YF = interpatient variability ofQ/F, olV21F = interpatient variability ofV2/F, ro 2ka =
interpatient variability ofka, cr2 =variance of residual error.
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Table 5. Comparison of Parameter Estimates for Adult and Pediatric Model
Development Dataset (80% of Data) on a Mean per kg Weight Basis

Parameters

Adult Parameter Estimate

CL/Fi_Ubtk_&=0,

1.9
11.5
3.3
40.6

v l /Fj_L/k_&= 02
_QIFJ!:.lhlk__gEe,
V2/F];::!k:&= ®•
ka(h'l=®s
Rj_~=®•

-2.9

Pediatric Model
Development
Parameter Estimate
2.1
9.7
4.5
71.7
1.86
3.4

Abbreviations: CL/F =oral clearance, Vl/F = oral volume of distribution in the central
compartment, Q/F = intercompartmental oral clearance, V2/F = oral volume of
distribution in the peripheral compartment, ka= first-order absorption rate constant, R=
zero-order absorption rate constant
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Table 6. Summary of Covariate Analysis (Model Development Dataset (80% ofData))

Covariate Anal~is
S~l Base Model
Step 2 Add single covariate onto Base Model
AgeonCL/F *
Weight on CL/F
Albuterol on CLIF
Weight on V2/F
Age on V2/F
Nausea on V2/F
Diphenhydrarnine on V2/F
Morphine on ka
Midazolarn on CLIF
Nausea on CL/F
Vancomycin on V2/F
Ticarcillin on CL/F
Anemia on CL/F
Colitis on V2/F
Furosemide on CL/F
Sulfarnethotrexate on CL/F
Pneumonia on V2/F
Ceftriaxone on CLIF
Cancer on V2/F
Ceftriaxone on V2/F
Amikacin on CL/F
Dopamine on CL/F
Height on V2/F
,
Fentanyl on V2/F
Ticarcillin on V2/F
Ceftazidime on V2/F
Amikacin on V2/F
Digoxin on CL/F
Albuterol on V2/F
Pneumonia on CL/F
Dopamine on Q/F
Weight on Q/F
Furosemide on V2/F
Sulfamethotrexate on V2/F
Vancomycin on CL/F
Age on ka
Vancomy_cin on ka
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Objective
Change in Objective
Function Value
Function Value
-2836.404
-2994.688
-2982.568
-2950.983
-2893.253
-2889.726
-2885.832
-2877.958
-2876.861
-2873.100
-2866.496
-2866.369
-2865.848
-2863.263
-2862.736
-2861.176
-2858.981
-2858.892
-2858.552
-2856.941
-2856.429
-2856.103
-2855.336
-2854.314
-2852.693
-2851.556
-2849.378
-2849.152
-2848.791
-2846.670
-2845. 137
-2842.936
-2842.341
-2842.154
-2841.608
-2841.493
-2840.979
-2840.791

158.284
146.164
114.579
56.849
53.322
49.428
41.554
40.457
36.696
30.092
29.965
29.444
26.859
26.332
24.772
22.577
22.488
22.148
20.537
20.025
19.699
18.932
17.9 10
16.289
15. 152
12.974
12.748
12.387
10.266
8.733
6.532
5.937
5.750
5.204
5.089
4.575
4.387

Objective
Change in Objective
Covariate Anal_2'Sis
Function Value
Function Value
Dopamine on V2/F
-2840.533
4.129
Ticarcillin on ka
-2840.486
4.082
Albuterol on ka
-2840.394
3.990
-2840.354
3.950
Weight on ka
Anemiaonka
-2840.133
3.729
Add single covariate onto base model
Step 3
lwith weight on CUF
Albuterol on CL/F
-3029.745
47.177
Weight on V2/F
-3017.325
34.757
Age on V2/F
-3013.095
30.527
-3007.163
Colitis on V2/F
24.595
Ticarcillin on CL/F
-3003.158
20.590
Morphine on ka
-3002.987
20.419
Ceftriaxone on V2/F
-3000.477
17.909
Age on CL/F
-3000.030
17.462
Sulfamethotrexate on CL/F
-2997.110
14.542
Anemia on CUF
-2996.912
14.344
Ceftriaxone on CUF
-2995.645
13.077
Albuterol on ka
-2995.220
12.652
Weight on Q/F
-2994.211
11 .643
Dopamine on Q/F
-2993.971
11.403
Furosemide on V2/F
-2992.992
10.424
Ticarcillin on ka
-2992.288
9.720
Ticarcillin on V2/F
-2990.290
7.722
Vancomycin on V2/F
-2989.823
7.255
Fentanyl on V2/F
-2989.478
6.910
Furosemide on CUF
-2989.346
6.778
Midazolam on CL/F
-2988.727
6.159
Ageonka
-2988.611
6.043
Weight on ka
-2988.255
5.687
Amikacin on V2/F
-2987.120
4.552
Dopamine on CUF
-2986.693
4.125
Vancomycin on ka
-2986.552
3.984
Amikacin on CL/F
-2985.769
3.201
Sulfamethotrexate on V2/F
-2985.578
3.010
Dopamine on V2/F
-2985.553
2.985
Diphenhydramine on V2/F
-2985.530
2.962
Cancer on V2/F
-2985.397
2.829
Vancomycin on CUF
-2985.362
2.794
Height on V2/F
-2985.131
2.563
Albutero1 on V2/F
-2985.095
2.527
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Covariate Anal~is
Ceftazidime on V2/F
Nausea on V2/F
Digman on CL/F
Pneumonia on CL/F
Nausea on CL/F
Pneumonia on V2/F
Step 4 Add single covariate onto base model
jwith weight on CL/F, and albuterol on CL/F
Weight on V2/F *
Age on V2/F *
AgeonCL/F *
Ceftriaxone on V2/F
Colitis on V2/F
Furosemide on V2/F
Ticarcillin on CL/F
Anemia on CL/F
Morphine on ka
Sulfamethotrexate on CL/F
Dopamine on Q/F
Ticarcillin on ka
Ticarcillin on V2/F
Weight onka
Amikacin on V2/F
Ceftriaxone on CL/F
Midazolam on CL/F
Age on ka
Dopamine on CL/F
Furosemide on CL/F
Albuterol on ka
Vancomycin on ka
WeisJ!! on_Q/F
Step 5 Add single covariate onto base model
with weight on CL/F, albuterol on CL/F, and
lceftriaxone on V2/F
Weight on V2/F
Age on V2/F
Age onCL/F
Morphine on ka
Furosemide on V2/F
Ticarcillin on CL/F
Dqp_amine on_Q/F
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Objective
Change in Objective
Function Value
Function Value
-2984.932
2.364
-2984.047
1.479
-2983 .903
1.335
-2982.725
0.157
-2982.570
0.002
-0.191
-2982.377

-3070.877
-3062.283
-3052.624
-3049.137
-3047.466
-3044.101
-3043 .946
-3040.798
-3040.763
-3038.156
-3035.479
-3035.289
-3034.070
-3033.796
-3033.720
-3032.002
-3030.397
-3030.153
-3029.803
-3029.751
-3027.386
-3025.119
-3023.072

41.132
32.538
22.879
19.392
17.721
14.356
14.201
11.053
11.018
8.411
5.734
5.544
4.325
4.051
3.975
2.257
0.652
0.408
0.058
0.006
-2.359
-4.626
-6.673

-3082.405
-3078. 131
-3074.059
-3062.637
-3061.865
-3057.697
-3057.359

33.268
28.994
24.922
13 .500
12.728
8.560
8.222

Objective
Change in Objective
Function Value
Function Value
Covariate Anal_r_sis
Colitis on V2/F
-3056.345
7.208
Ticarcillin on ka
-3054.317
5.180
-3054.127
4.990
Weight onka
Ticarcillin on V2/F
-3053.223
4.08~
Amikacin on V2/F
-3052.872
3.735
-3050.762
Sulfamethotrexate on CL/F
1.625
-3050.621
Anemia on CL/F
1.4811
Add single covariate onto base model
Step 6
with weight on CL/F, albuterol on CL/F,
ceftriaxone on V2/F, and weight on V2/F
Age onCL/F*
-3096.981
14.576
Dopamine on Q/F
-3089.298
6.893
Morphine on ka
-3088.954
6.549
Weight onka
-3087.621
5.216
-3087.414
Ticarcillin on ka
5.009
-3086.086
3.681
Ticarcillin on CL/F
Furosemide on V2/F
-3085.382
2.977
-3084.643
2.238
Ticarcillin on V2/F
-3083.425
1.020
Age on V2/F
Colitis on V2/F
-3082.406
0.001
Add single covariate onto base model
Step 7
with weight on CL/F, albuterol on CL/F,
lceftriaxone on V2/F, weight on V2/F, and
~oparnine on Q/F
Age on CL/F •
-3102.415
13.117
Morphine on ka
-3094.727
5.429
-3094.110
Ticarcillin on ka
4.812
Weig_ht on ka
-3092.860
3.562
Step 8
Add single covariate onto base model
with weight on CL/F, albuterol on CL/F,
jceftriaxone on V2/F, weight on V2/F, dopamine
on Q/F, and morphine on ka
Ticarcillin on ka
-3095.264
0.537
• 95% confidence interval of parameter estimate includes the null value.
Abbreviations: CL/F = oral clearance, Q/F = intercompartmental oral clearance, V2/F =
oral volume of distribution in the peripheral compartment, ka= first-order absorption rate
constant
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Table 7. Backward Elimination Results from Full Model (Model Development Dataset
( 80% ofDataJl: FO Method
Pj11111lleter
Change in
Value of
p Value
parameter
objective
function value
CL/F
Weight
01=0
89.5
< 0.005
0,=0
Albuterol
57.0
< 0.005
V2/F
9.5
Ceftriaxone
09=0
< 0.005
33.3
< 0.005
01 0=0
Wei&!!!
Q/F
011=0
6.9
NS
D~arnine
ka
012=0
5.4
NS
M~hine
Abbreviations: FO----first order, CL/F = oral clearance, V2/F = oral volume of distribution
in the peripheral compartment, Q/F = intercompartmental oral clearance, ka= first-order
absorption rate constant, NS=not significant.
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Table 8. Final Model Equations, Parameter Estimates, Percent Relative Standard Errors
(%RSE), and 95% Confidence Intervals (Model Development Dataset (80% of Data)) FO Method

Parameters

Estimated
Value

%RSE

95% Confidence
Intervals

43.9
1.22
- 20. l
258
110

14.6
24.3
20.4
12.7
10.6

31.4,56.4
0.64,1.80
-28.1 ,-12.1
194,322
87,133

1270
-588
32.4
1.81
105
0.769
0.286

14.8
18.9
20.4
15.5
14.6
39.5
44.I

---

---

2.26
0.23

36.3
20.0

902,1638
-806,-370
19.5,45.3
1.26,2.36
75 ,135
0.173, 1.365
0.039,0.533
--0.65 ,3.87
0. 14,0.32

CL/F (Uh)=01 + <"),·weight+
®s·albuterol
®,
®,
®s
Vl!F(I.:)= ®2
~IF]Qii}_= ®,
V2/F (L)= ®•+ ®9·cefr+ ®1o·weight
®·
09
®10
ka]i5:= ®s
RIm:::&/iil= ®•
2

ro cUF
(j)~
ro'V21F

ffi2..
__t_

Abbreviations: FO=first order, CL/F =oral clearance, Vl/F = oral volume of distribution
in the central compartment, Q/F = intercompartmental oral clearance, V2/F = oral
volume of distribution in the peripheral compartment, ka= first-order absorption rate
constant, R= zero-order absorption rate constant, ro2cUF =interpatient variability ofCL/F,
ro 2QIF = interpatient variability ofQ/F, ro2V21F = interpatient variability ofV2/F, ro\, =
interpatient variability ofka, o 2 =variance ofresidual error, cefr=ceftriaxone use.
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Table 9. Predictive Performance of Azithromycin Population Pbarmacokinetic Model
for Validation Dataset (20% of Data)- FO Method
Parameter

Value (ug/mL)

s.d. (ug/mL)

0.1644
0.1026
0.0167
0.1016
Abbreviations: FO=first order, s.d.= standard deviation
Precision

Bias
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95% Confidence Interval

J\lg/_mJd
J:o.078l ,o.122n:
(0.0001,0.0334)

Table 10. Final Model Equations, Parameter Estimates, Percent Relative Standard
Errors (%RSE), and 95% Confidence Intervals with 100% of the Pediatric Data using
FO Method

Parameters

Estimated
Value

%RSE

95% Confidence
Intervals

43.5
1.47
-20.7
307
114

15.9
20.0
25.l
14.8
10.8

29.9,57.1
0.89,2.05
-30.9,-10.5
218,396
90,138

1230
-597
38
1.94
106
0.887
0.293

13.3
19.3
26.0
14.9
12.4
38.7
39.6
--38.9
25.4

911 , 1549
-822,-372
26,50
1.37,2.51
80,132
0.215,1.559
0.066,0.520
--0.54,3.98
0.16,0.46

CL/F (L/h)=01 + E>1·weight+
e,·albuterol
e,
e,
e,
Vl!F(i:)= 02
[QIF(Lib)= 0 3
V2/F (L)= ®•+ 09·cefr+ 0 10·weight
e,
09
010
ka(h-=l)= Els
R(mg/h)= e 6
ffi2cUF

o70/F
o7V2/F

---

~

2.26
0.31

~.

Abbreviations: FO=first order, CL/F =oral clearance, Vl/F =oral volume of distribution
in the central compartment, Q/F = intercompartmental oral clearance, V2/F = oral
volume of distribution in the peripheral compartment, ka= first-order absorption rate
constant, R= zero-order absorption rate constant, oi2cUF =interpatient variability ofCL/F,
2
2
oi Q!F = interpatient variability ofQ/F, oi v21F = interpatient variability ofV2/F, oi'•• =
interpatient variability ofka, u 2 =variance ofresidual error, cefr=ceftriaxone use.

65

Table 11 . Final Model Equations, Parameter Estimates, Percent Relative Standard
Errors (%RSE), and 95% Confidence intervals with 100% of the Pediatric Data Using
FOCEMethod

Parameters

Estimated
Value

%RSE

95%
Confidence
Intervals

18.2
2.25
134
103

31.3
14.3
21.3
I I.I

7.1,29.4
1.62,2.88
78,190
81 ,125

1180
26.9
0.656
187
0.428
0.761
0.287

14.2
15.4
17.2
28.3
20.0
40.2
22.1

851,1510
18.8,35.0
0.435,0.877
83,291
0.260,0.596
0.160, 1.360
0.163,0.411

CUF (L/h)=El 1 + @,-weight
e,
81
Vl!F-(L)= 8 2
_Q_IF (Llh)= e,
V2/F (L)= ®•+ Ela·weight
e.
Ela
kal!O._=e,

RJ:m~= El6
ffiTcUF
2

ffi ka

cl

Abbreviations: FOCE=first order conditional estimation, CUF =oral clearance, Vl/F =
oral volume of distribution in the central compartment, Q/F = intercompartmental oral
clearance, V2/F =oral volume of distribution in the peripheral compartment, ka= firstorder absorption rate constant, R= zero-order absorption rate constant, ro2cUF
=interpatient variability ofCL/F, ro2., = interpatient variability ofka, cl =variance of
residual error.
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Table 12. Predictive Performance of Azithromycin Population Phannacokinetic Model
for Validation Dataset (20% of Data)- FOCE Method
Value (ug/mL)

s.d. (ug/mL)

95% Confidence Interval
J!!gLmL..2_
Precision
0.1048
0.1699
J:o.0191,o.12STI::
0.0236
0.1025
Bias
J:o.0068,0.040~
Abbreviations: FOCE=first order conditional estimation, s.d.= standard deviation
Parameter
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Figure I . Observed Azithromycin Serum Concentration versus Predicted Azithromycin
Serum Concentration Values for the Base Model (80% of data) - FO Method
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Figure 2. Residuals versus Predicted Azithromycin Serum Concentration Values for the
Base Model (80% of data) - FO Method
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Figure 3. Weighted Residuals versus Predicted Azithromycin Serum Concentration
Values for the Base Model (80% of data) -FO Method
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Figure 4. CL/F versus Weight for Base Model parameter estimates (80% of data) - FO
Method
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Figure 5. CUF versus Albuterol for Base Model Parameter Estimates (80% of data) FOMethod
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Figure 6. V2/F versus Weight for Base Model Parameter Estimates (80% of data) - FO
Method
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Abbreviations: V2/F =oral volume of distribution in the peripheral compartment,
FO=first order
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Figure 7. V2/F versus Ceftriaxone for Base Model Parameter Estimates (80% of data)FOMethod
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Abbreviations: V2/F = oral volume of distribution in the peripheral compartment,
FO=first order
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Figure 8. Observed Azithromycin Serum Concentration versus Predicted Azithromycin
Serum Concentration Values for the Validation Dataset (using Final Estimates from Final
Model with 80% data) - FO Method

0.8

0
0

i

~ 0.6

0

!!!

c
"'
5
u

0

0

0

0

·[ 0.4
E

0

e

0

0

0

E

0

° o... . ·

8

~

0

al 0.2 2:

"'
ll

0

0

0

0.0

0.2

0.0

0.4

0.6

Predicted Azithromycin Concentration (ug/ml)

Abbreviations: FO---first order

75

0.8

(

Figure 9. Weighted Residuals versus Predicted Azithromycin Serum Concentration
Values for the Validation Dataset (using Final Estimates from Final Model with 80%
data) - FO Method
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0

0

Figure I 0. Observed Azithromycin Serum Concentration versus Predicted Serum
Azithromycin Concentration Values for 100% of the Pediatric Data Using FO Method
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Figure 11. Observed Azithromycin Serum Concentration versus Individual Predicted
Serum Azithromycin Concentration Values for 100% of the Pediatric Data Using FO
Method
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Figure 12. Residuals versus Predicted Azithromycin Serum Concentration Values for
I 00% of the Pediatric Data Using FO Method
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Figure 13. Weighted Residuals versus Predicted Azithromycin Serum Concentration
Values for I 00% of the Pediatric Data Using FO Method
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Figure 14. Observed Azithromycin Serum Concentration versus Predicted Serum
Azithromycin Concentration Values for 100% of the Pediatric Data Using FOCE
Method
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Figure 15. Observed Azitbromycin Serum Concentration versus Individual Predicted
Serum Azitbromycin Concentration Values for I 00% of the Pediatric Data Using FOCE
Method
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Figure 16. Residuals versus Predicted Azithromycin Serum Concentration Values for
100% of the Pediatric Data Using FOCE Method
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Figure 17. Weighted Residuals versus Predicted Azithromycin Serum Concentration
Values for 100% of the Pediatric Data Using FOCE Method
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Figure 18. Observed Azithromycin Serum Concentration versus Predicted Azithromycin
Serum Concentration Values for the Validation Dataset (using Final Estimates from Final
Model with 80% data) - FOCE Method
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Figure 19. Weighted Residuals versus Predicted Azithromycin Serum Concentration
Values for the Validation Dataset (using Final Estimates from Final Model with 80%
data) - FOCE Method
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Figure 20. Observed and Predicted Azithromycin Serum Concentration Values versus
Time for the Validation Dataset (using Final Estimates from Final Model with 80% data)
- FOCE Method

~08

2.

•

•

c

g
~

c

g0.6

•

0

0

••

c

·5

>-

E
l: 0.4
0

~

"O
Q)

0

'O
Q)

it 0.2
"O

c

al"'
C'.
Q)

~ 0.0

•

•

~

(

8

ii ' "' .~·...
0

0

I\

•

0

50

•

~··1: Ki · ~ . ..0

.

100

150

Time (hours)

Open Circle: Observed Serum Concentration
Closed Circle: Predicted Serum Concentration
Abbreviations: FOCE=first order conditional estimation

87

200

250

MANUSCRIPT ill

Population Phannacokinetics of Prednisolone in Heart and Lung Transplant
Patients

ABSTRACT

A population pharmacokinetic analysis was conducted for prednisolone on data from
thoracic organ transplant patients. The data consisted of 496 plasma prednisolone
concentrations and 496 plasma prednisone concentrations from 41 patients administered
total daily oral doses of prednisolone ranging from 5-80 mg per day. A population
pharmacokinetic analysis was conducted in NONMEM on estimated unbound
prednisolone concentrations. A one compartment model with first order rate of
absorption was found to best fit the data. Potential covariates were assessed for oral
clearance (CL/F) and oral volume of distribution (VIF). Sex and concurrent
ciprofloxacin use were found to be significant covariates for CL/F. No covariates were
found to be significant for V/F. Neither age, weight, type of transplant, presence of
cystic fibrosis, or concurrent use of acyclovir, amphotericin, cefotaxime, ceftazidime,
flucloxacillin, ganciclovir, imipenem, itraconazole, lyposomal amphotericin, nor septrin
appeared to be significant for any pharmacokinetic parameter. The unbound
prednisolone and total prednisone concentration data were simultaneously modeled using
the final parameter estimate of the apparent volume of distribution from the analysis of
prednisolone alone and a literature value for the apparent volume of distribution of
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prednisone was used. It was not possible to obtain meaningful models for the
simultaneous modeling of the prednisolone/prednisone data.
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INTRODUCTION
Prednisolone, a synthetic corticosteroid, is an important imrnunosuppressant used in
organ transplant patients to suppress allograft rejection. Transplant patients are often
treated chronically with empirically determined prednisolone doses (1;2). Because of the
lack of individual dosing regimens, the tendency for increased serious adverse events or
sub-therapeutic concentrations is great. The future of imrnunosuppression therapy will
be geared towards individualizing a patient's dose (3).

General steroid information
Corticosteroids are prescribed for their imrnunosuppressive and anti-inflammatory
effects. These effects are produced by the binding of the steroid to cytosolic receptors in
many different tissues. These activated receptors then go on to the cell nucleus and
increase the transcription of certain genes that regulate the synthesis of specific proteins,
second messengers, or enzymes (2). Some effects are seen immediately (e.g. changes in
cortisol plasma concentrations) and appear directly related to the pharmacokinetics of
the steroid; other effects (e.g. eosinophil counts), have a slow onset (6-8 hours) and slow
dissipation of the response (24-36 hours) back to baseline (2;4).

Because steroids are nonselective immunosuppressants (i.e. they affect many genemediated responses simultaneously), these drugs may predispose patients to a greater
risk of infections and other side effects (5). These adverse events may include:
cushingoid features, hemorrhage, psychoses, myopathy, osteoporosis, cataracts,
hyperlipidemia, growth retardation in children, and hypertension (2;6-8) . Often the
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frequency of side effects are increased in patients undergoing chronic therapy, patients
with low serum albumin concentrations, and patients receiving certain concomitant
medications (e.g. oral contraceptives) that affect the protein binding and metabolism of
prednisolone; all factors that increase a patient's steroid exposure. Patients with low
serum albumin concentrations may have greater steroid exposure due to altered protein
binding and/or a reduced hepatic function (2;9). A study of240 medical inpatients
receiving prednisone showed a correlation between the frequency of side effects, the
mean daily prednisone dose, and the serum-albumin levels. Side effects were more
common with those patients that received higher prednisone doses and in patients with
low serum-albumin concentrations ( 4;9).

Prednisolone Pharmacokinetics
For immunosuppression of organ transplants, prednisolone is administered either orally
or intravenously. When prednisolone is administered orally, it is administered as
prednisolone or as its prodrug prednisone, which is metabolized to active prednisolone
(2;10;11).

Absorption
Oral prednisolone has a bioavailability (F) of60-100% (2;11-14). The lower
bioavailability has been seen with higher steroid doses. Patients who exhibit subtherapeutic responses with prednisolone often experience poor absorption of drug ( 4).
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Prednisolone has a prompt rate of absorption with a peak concentration (Cmax)
occurring between one and two hours post dose (Tmax) (1;2;4;15-17).

Distribution
The reversible binding of drug to proteins follows the law of mass action:

(Dj+(P) :: (DP)
where D= the molar concentration of unbound drug, P= the unoccupied protein, DP=
the drug protein complex, k 1= the forward rate constant, and k2= the reverse rate
constant. The ratio ofkl/k2 is known as the equilibrium association constant or affinity
constant (Ka) (18;19). Ka provides information as to the affinity between the drug and
its binding site on the protein; drugs that are strongly protein bound have large values of
Ka (19). The inverse of Ka (i.e. I/Ka) is known as the equilibrium dissociation constant
(Kd).

A drug' s extent and ability to bind to proteins will affect its pharmacokinetic parameters,
specifically clearance and volume of distribution ( 18; 19). In the typical therapeutic
concentration range for most drugs, the fraction unbound remains constant; only a small
fraction of the binding sites on proteins are occupied. For a given concentration of
protein, the fraction unbound is constant. Consequently, the pharmacokinetic
parameters of most drugs are independent of dose (19) . However, for some drugs,
protein binding varies with concentration level and thus these drugs exhibit concentration
dependent pharmacokinetics.
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Plasma protein binding of prednisolone appears to be dose related, resulting in nonlinear
pharmacok:inetics (2;4;10;16;17;20-24). The nonlinearity is attributed to prednisolone
binding to two different proteins; transcortin (i.e. corticosteroid binding globulin) which
exhibits a low capacity and high affinity for prednisolone and albumin which exhibits a
high capacity and low affinity for prednisolone (2;4;9;20;23-27). Prednisolone protein
binding can be expressed:

D• = N,P,K,Dr + NaPaKaDr
(I+ K·Dr) (1 + KaDr)
where Db is the concentration of prednisolone bound to both transcortin and albumin
sites, N, is the number of binding sites for transcortin,

K. is the affinity constant for

transcortin, P, is the molar concentration oftranscortin protein, N, is the number of
binding sites for albumin, K, is the affinity constant for albumin, P, is the molar
concentration of albumin, and Dr is the unbound concentration of prednisolone
(16;23;24;28;29). Assuming K,D,<< l , there is one prednisolone binding site per
molecule of albumin, and prednisolone only binds to transcortin and albumin
(16;23;24;28;29), then bound concentration ofprednisolone can be reduced to:

D• = N, P,K,DJ +PaKaDr
(1+ K;Dr)

Nonlinear prednisolone protein binding occurs because of limited concentrations of
transcortin in plasma (24). At low concentrations of prednisolone, binding to transcortin
is maximal at 90-95%, but at large concentrations, saturation occurs thus producing only
60% transcortin binding (2;4;10;24;30). Therefore at low doses, the increased fraction
bound of prednisolone to transcortin makes less prednisolone available to distribute to
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receptor sites (2). The binding capacity (N1P 1) and Ka of prednisolone to transcortin
7

7

have been reported to be (5 .45-8.00)xl0- Mand (l .40-3.39)xl 0 UM respectively
(2;9;18;28;3 l). The normal concentration of transcortin in plasma is approximately 0. 7
µM and falls in proportion with serum-albumin levels (9). It is thought that only
unbound prednisolone is biologically active (4; 10;22). Cortisol also complicates the
binding ofprednisolone since it competes with prednisolone for binding sites to
transcortin (31 ). There appears to be a circadian cycle affecting the binding capacity of
transcortin to prednisolone; binding is least at 8a.m. when cortisol levels are high and
greatest at midnight when cortisol levels are low (2;32).

The other protein that prednisolone extensively binds to is albumin. The binding
capacity (N,P,) and Ka ofprednisolone to albumin have been reported to be (6.237.00)xl04 Mand (1.40-3.00) x 103 LIM, respectively (2;9;24;28;3 l). The normal
concentration of albumin in plasma is 35-55 g/L (2; 19;3 l ). Albumin concentration
decreases with age and is lower in cystic fibrosis patients (19).

At oral prednisolone doses of l 5mg and 50mg, the protein binding of prednisolone has
been reported at 87% and 74% respectively (19). The dose dependency ofprednisolone
pharmacokinetics has been primarily attributed to nonlinear protein binding ( 4). The
apparent steady state volume of distribution based on total and unbound prednisolone
concentrations were reported to be 35-114 Land 323-530 L respectively for doses
ranging from 1.25 mg eight times daily to I 00 mg once daily; larger doses produced
larger values total prednisolone volume of distribution, while the free prednisolone
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volume of distnbution was not dose dependent (17). The apparent volume of
distribution for total prednisone was reported to be 0.97 L/kg (33).

Metabolism
Prednisolone is extensively metabolized by both the liver and kidney (2;10;22;34).
Prednisolone and prednisone undergo biotransforrnation to a variety of oxidation
products (4;24;35). The four most important metabolites for prednisolone reported are:
prednisone, 20-13-hydroxyprednisolone,

6-~-hydroxyprednisolone,

and 20-a-

hydroxyprednisolone. Another minor metabolite that has been reported is 20-~
hydroxyprednisone ( 11 ).

As discussed earlier, the bioavailability of prednisolone is high, thus there is limited
presystemic metabolism of prednisolone (36). Prednisolone displays restrictive
clearance; clearance is sensitive to fraction unbound in the plasma and the activity of the
drug metabolizing enzymes (2; 19;34).

Prednisolone undergoes reversible metabolism (interconversion) to prednisone. The
enzyme

11-~-hydroxydehydrogenase

is responsible for the interconversion process

(IO; 13 ;20). Prednisone is also reconverted back to prednisolone. The interconversion of
prednisolone and prednisone has been reported to be a nonlinear process. This
nonlinearity can be seen in the area under the concentration versus time curve (AUC) for
prednisolone and prednisone. The ratio of AUC prednisolone/ AUC prednisone increases
with increasing doses ofprednisolone (2;11;20;24). lfthe interconversion were linear,
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the ratio of the AUCs would remam constant with increasing doses; as the concentration
of one of the steroids increases, the other steroid would increase in a proportional
manner.

Prednisolone dominates the interconversion process and the prednisolone

concentrations can be as much as 10 times the prednisone concentrations (2;4;11;21;24).
The dose-dependent interconversion of prednisone and prednisolone complicates an
assessment of the phannacokinetic parameters ofprednisolone (2;22;24;29).
Conventional linear pharmacokinetic parameter calculation methods that assume no
interconversion underestimate clearance and overestimate volume of distribution (37).
The absence of an intravenous formulation of prednisone for humans makes the exact
assessment of the interconversion process difficult (I 0).

Excretion
The unchanged prednisolone and metabolites recovered in the urine from a dose of
intravenous prednisolone are reported to be approximately 42% (11). Prednisolone,
prednisone, and

6-~-hydroxyprednisolone

recovered in the urine are reported to be

approximately 20%, 2%, and 6-10% of the dose respectively (2;4;11 ;13;38). Three
other metabolites, 20-~-hydroxyprednisolone, 20-a-hydroxyprednisolone,

20-~

hydroxyprednisone have reported values recovered in urine around 7%, 5%, and 0.6%
respectively ( I I).

Garg et.al. preformed an extensive analysis on the interconversion ofprednisolone and
prednisone (11). They performed a two-way crossover study between two treatments:
oral prednisone tablets and intravenous prednisolone sodium phosphate. They found the

96

irreversible elimination clearances ofprednisone and prednisolone to be 53 .9 mVmin and
196 mVmin respectively. The clearance for the conversion ofprednisolone to prednisone
was reported as 836 mVmin. The clearance for the conversion of prednisone to
prednisolone was reported as 8822 mVrnin; I 0 times higher then the clearance of
prednisolone to prednisone. Since the clearance of prednisone not reconverted to
prednisolone was relatively small and the clearance of prednisone reconverted to
prednisolone was relatively high, this implied that most prednisone was converted to
prednisolone. The recycled fraction (RF), the probability of a molecule being converted
to its metabolite and back at least once, was reported to be 0.76 for prednisolone. A
large RF indicates a greater role of interconversion between a drug and its metabolite. A
RF of0.76 suggests that a large interconversion process occurs between prednisolone
and prednisone (11).

As reported by Jusko et. al. , in a study with six normal male subjects dosed 5mg, 20mg,

and 50mg oforal prednisone, the oral clearance of total prednisolone was around 8, 12,
and 16 L/h respectively (4). The increase in oral clearance was statistically significant.
Rohatagi et.al. found similar results for oral clearance of total and unbound prednisolone
to be 6-19 L/h and 64-128 L/h respectively across oral prednisolone doses of 1.25 mg
eight times daily- I 00 mg once daily (17). These investigators found dose dependent
increases in clearance based on total but not unbound concentrations. The mean oral
clearance of prednisone was reported to be 0.216 Lib/kg (39). It has been reported that
prednisone does not exhibit nonlinear protein binding (I 0).
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Nonlinearity of Prednisolone Pharmacokinetics
Total prednisolone concentrations exhibit both dose-dependent clearance and dose
dependent steady state volume of distribution (2;4;1O;16;17;24;37). Saturation of
prednisolone binding to plasma transcortin, a saturation of the interconversion processes,
saturation of elimination pathways, concentration dependent clearance of unbound
prednisolone concentrations, and tissue-binding sites may all be responsible for the dose
dependency (10;37) . Apparent clearance and steady state volume of distribution increase
two fold between 5-40mg ofprednisolone (2;16;20;24;40). Because of the nonlinearity
seen with total prednisolone concentrations, it has been recommended that unbound
prednisolone concentrations be measured (2 ;24). When using unbound prednisolone
concentrations, both clearance and steady-state volume of distribution become more
constant with dose (l 7;23). However, some investigators report that some nonlinearity
still exists. The remaining nonlinearity has been proposed to be caused by nonlinear

renal clearance, dose dependency of the interconversion process, and differences in the
degree of nonlinearity in the disposition of prednisolone and prednisone
(4;10;11;20;24;35;40).

The half-life of unbound prednisolone appears to remain constant (range= 2.3-3.5 hours;
mean=2.9 hours) over different doses. This is probably because the volume of
distribution and clearance are equally affected by nonlinear effects (2;4; 11; 17).
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Prednisolone population characteristics
Table I provides a comparison of some population pharmacokinetic parameters.

Age
One study reported tbat total prednisolone clearance was not different between children
and adults (41), while another study found a 49% higher clearance (on a per kg basis) in
children younger than 12 years of age than children over 12 years (42). No information
was found regarding volume of distribution in children. Compared to young adults,
elderly patients have a higher frequency of adverse events, lower unbound prednisolone
clearance (Table I) and smaller unbound prednisolone steady-state volume of
distribution (14). These differences have been attributed to a decrease in both renal and
nonrenal clearances. The clearance of 6-P-hydroxyprednisolone decreases linearly with
the nonrenal clearance of unbound prednisolone, thus indicating the activity of liver
enzymes responsible for prednisolone metabolism diminishes in the elderly (24).

Gender
While gender has been found to alter the pharmacokinetics of prednisolone, there have
been reported differences in the effect. In two studies, both unbound and total
prednisolone clearances in adults were reported as being 20% greater in females than
males (Table I) (40;43). No statistically significant differences in gender were found in
volume of distribution for unbound and total prednisolone ( 40). In another study,
Magee et.al. reported tbat unbound prednisolone clearance normalized to total body
weight was approximately 20% higher in white males and 40% higher in black males as
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compared to females ( 44). The unbound prednisolone apparent volume of distribution
normalized to total body weight was approximately 30% higher in white males and 40%
higher in black males than females (44).

Concomitant Medications
Inducers
It has been reported that the metabolism of prednisolone increased when administered
concomitantly with anticonvulsants or rifampicin (2;4; I 0;22). Phenytoin increased both
the total clearance (48%) and nonrenal clearance (77% females; 65% males) of unbound
and total prednisolone (Table I} (2;4;43;45). The increase in total clearance was due to
the increase in nonrenal clearance. The urinary excretion of 6-P-hydroxyprednisolone
was greater post phenytoin dosing ( 43). Phenytoin does not affect prednisolone' s
volume of distribution, protein binding, or renal clearance (24;43).

Inhibitors
The metabolism of prednisolone was inhibited when administered concomitantly with
oral contraceptives. Oral contraceptives cause: I) a decrease in unbound prednisolone
clearance and steady-state volume of distribution, 2) an increase in serum transcortin
concentrations, 3) an increase in half-life, and 4) lower affinity constants for both
prednisolone-albumin and prednisolone-transcortin complexes
(2;4;15 ;22;27;29;30;38;46). Three studies compared the effects of oral contraceptive
use with different doses of prednisolone. Total prednisolone clearance, unbound
prednisolone clearance, and total prednisolone volume of distribution were all lower in
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oral contraceptive users than the control cohort (Table 1). The lower values for total
body clearance were attributed to a reduction in nonrenal clearance and increased
cortisol binding to transcortin (27;29;30). The reduction in nonrenal clearance has been
attributed to a reduction in the activity of hepatic

6~-hydroxylase

(27). Plasma cortisol

concentrations have been reported as being twice as high in oral contraceptive users
(30;46). At lower doses of prednisolone; cortisol displaces prednisolone from transcortin
binding sites but not albumin binding sites (40;46). Oral contraceptive users have
decreased unbound prednisolone clearances at low doses ofprednisolone as compared to
high doses (30;40).

Inhibition of predniso lone metabolism has also been seen with concomitant
administration of other medications. Concomitant administration of diltiazern resulted in
a reduction of the total clearance ofprednisolone (Table I), while naproxen and
indomethacin reduced the clearance of unbound prednisolone by 35% and 40%
respectively (2;4 7). Two studies found minor or no changes in AUC and half-life of
prednisolone when given concomitantly with itraconazole (36;48). Both analyses
concluded that CYP3A4 was a subsidiary pathway for prednisolone metabolism.
Zurcher et.al. found that ketoconazole, a potent inhibitor ofCYP3A4, decreased the
total body clearance and volume of distribution of both unbound and total prednisolone.
The AUC of unbound prednisolone increased by 50% with concurrent ketoconazole use.

It was proposed that ketoconazole decreases renal clearance by impaired tubular
secretion and nonrenal clearance by inhibited

6~-hydroxylase

activity. Since the unbound

prednisolone volume of distribution decreased while transcortin and albumin levels

IOI

remained constant, they concluded that altered protein binding was not the reason for the
reduction in volwne of distribution; the mechanism that reduced the volume of
distnbution was not known (13). Contrary to Zurcher's findings, Yamashita et.al. found
no significant inhibition with concomitant ketoconazole use ( 49). In summary, the role
of the CYP450 enzyme system with prednisolone pharmacokinetics remains unknown.

Cystic Fibrosis (CF)
Prednisolone clearance and steady-state volwne of distribution were approximately 50%
higher in adolescent CF patients compared to a control cohort of age matched adolescent
asthmatic patients (50). It is believed that enhanced biotransformation is the underlying
reason for the differences seen in clearance; more frequent steroid doses may be
necessary in the treatment of CF patients (50) .

Additional differences in pharmacokinetic parameters were seen comparing CF patients
with normal subjects. Dove et.al. found that the total prednisolone nonrenal clearance
and unbound fraction of prednisolone were larger in CF patients. Albumin and total
protein serum concentrations for CF are low; therefore increased volume of distribution
could be related to decreased protein binding (50).

Menopause
After a 25mg intravenous and 30mg oral dose of prednisolone in premenopausal and
postrnenopausal women, Harris et.al. found that total and unbound prednisolone
clearances were smaller and half-lives were larger in postmenopausal women (Table 1).
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There were n<i observed significant differences in volume of distribution, protein binding,
or bioavailability ofprednisolone between these groups of women. They proposed that a
change in the activity ofat least one enzyme system involved in the metabolism of
prednisolone occurs in postmenopausal women (34).

Prednisolone specifics in organ transplantation patients
Rejection levels have been shown to be similar between high and low prednisolone
clearance groups. While rejection levels were similar, an increased frequency ofrejection
and corresponding allograft loss was found in high prednisolone clearance patients; the
number of rejection episodes has been shown to be an important risk factor for allograft
failure (1;2;5;10;51;52). Combination drug therapy (e.g. cyclosporine) is typically used
for adequate immunosuppression and to minimize adverse events (38;52;53). Bergrem
el. al. evaluated cushingoid versus non-cushingoid transplant patients taking I Omg oral

prednisolone and found that cushingoid patients had lower total and unbound
prednisolone clearances (Table I). The cushingoid patients had a poorer transplant
function than the non-cushingoid patients, as determined by creatinine clearance ( 15). In
a renal transplant study conducted by Ost et.al., the total prednisolone clearance in
cushingoid patients did not differ from non-cushingoid patients (I).

Specific Aims of this Research
Ultimately, the goal of immunosuppression is to taper the dose of prednisolone and
eventually switch a patient to either the lowest efficacious dose or an alternate-day
therapy regimen while not compromising a patient's therapeutic response (2; I 0). Steroid

103

dosage is tapered as rapidly as possible after transplantation, although without an
objective guide to safe steroid withdrawal, this can hasten recurrent rejection (5). The
overall patient survival rate is linearly correlated with frequency of rejection episodes; i.e.
the more episodes, the less likely a patient is to survive (5;51;52). Ideally, a reduction in
the maintenance dose is warranted if the disease symptoms are under control or if
transplanted organ function is suitable (2). It is desirable to develop an individualized
dosing regimen for prednisolone based on measurable parameters (23).

An understanding of the time course of concentration values would be helpful to

optimize irnmunosuppressive therapy. To date, a population pharmacokinetic study of
prednisolone has not been performed in humans. The intent of this research is to develop
a population pharmacok.inetic model of prednisolone, which can be used to optimize the
dosing regimen of prednisolone in organ transplant patients.

Specific aims of this research are:
I)

To develop a population pharmacokinetic model for prednisolone including oral
clearance (CL/F) and oral volume of distribution (V IF) and to assess the
interindividual variability in thoracic organ transplant patients

2) To investigate various individual characteristics such as demographic
information, disease status, and concomitant medications as potential covariates
to reduce interindividual variability
3) To develop population pharmacok.inetic models for the evaluation of the optimal
prednisolone dosing based on individual characteristics.
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METHODS AND MATERIALS
Patients. A randomized, open-label clinical trial was conducted in 50 thoracic organ
transplant patients to compare the pharmacok:inetics and pharmacodynamics of two
cyclosporine formulations (Neoral, the microemulsion formulation (n=28) versus
Sandimmune, the original formulation (n=22)). The appropriate institutional review
boards approved the protocol. The patients, prior to inclusion in the trial, gave written
informed consent. The trial was conducted over the first postoperative year after organ
transplant, with supplementary visits occurring approximately at the end of weeks I, 2,
3, and 4 and at the end of months 3 (week=l2), 6 (week=26), 9 (week=38), and 12
(week=52) . Results from this trial have been previously published by A. Trull et.al. (51).

Of the 50 patients, 41 patients had serum samples that were assayed for prednisolone,
prednisone, and cortisol on at least one of the supplementary visits. These 41 patients
had the following types of transplants: heart and lung (n=I 9), double lung (n=7), or
single Jung (n= 15) transplant. This retrospective data analysis was conducted on all of
the 41 patients with measurable prednisolone concentrations. Characteristics of the
patients are presented in Table 2.

Prcdnisolonc Administration.
The dosing of prednisolone was individualized for each patient. Initially, a patient was
dosed with a large dose (maximum dose of 40mg) ofprednisolone every 12 hours
(maximum daily dose of 80mg). Each day, the total daily dose of prednisolone was
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reduced by Smg (or in some cases 2.Smg) until the lowest possible maintenance dose
was achieved for the patient. The larger doses ofprednisolone (e.g, 25mg) were
supplied by Hoechst Marion Roussel (West Malling, Kent), while the smaller doses (e.g.
Smg) were supplied by either APS Ltd (Eastbourne, East Sussex) or CP Pharmaceuticals
Ltd (Wrexham, Clwyd). The dosing interval was increased to 24 hours once a daily
dose of l 5-20nig was achieved. Figure I shows the distribution of doses by plotting the
percent of concentration samples versus the dose given.

A patient continued on the lowest daily maintenance dose unless they started to reject
their transplant. Rejection episodes were treated with high intravenous doses (500-1000
mg/day) ofmethylprednisolone over a period of three consecutive days. Ifa dose of
methylprednisolone was given the day prior, or on the day of the sample collection, then
the sample collection was not used in this analysis (64 records).

Table 3 provides a partial account of the dosing history for patient #4. Patient #4
received a total daily dose of 50mg on day I. The total daily dose was reduced by Smg
each day thereafter until day 8. The patient began to have symptoms of organ rejection
and on day 11 they were dosed with intravenous methylprednisolone. The
methylprednisolone treatments continued until day 14. On day 14, the patient once again
started on a high oral prednisolone dose, and continued the Smg step down in dose until
day 22. The same dosing pattern was followed for the rejection episode that occurred
on day24.
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Blood Collection and Sample Analysis.
Plasma samples were collected from patients approximately at the end of weeks I , 2, 3,
and 4 and at the end of months 3 (week=12), 6 (week=26), 9 (week=38), and 12
(week=56). The primary objective for the study was to collect cyclosporine
concentrations at these visits for each patient. If enough sample remained, then an
additional assay was conducted for total prednisolone, total prednisone, and total
cortisol. Measurements of total prednisolone, total prednisone and total cortisol were
made using a fully validated high-performance liquid chromatography (HPLC) technique
as descnlled in a previous publication (54).

Of the concentration records that were obtained, if the values ofprednisolone,
prednisone, and cortisol were all equal to 0, then that record was removed. Thus there
remained a total of 496 prednisolone and 496 prednisone concentrations (n=992
concentration values). The lower limit of detection (LLD) and lower limit of
quantification (LLQ) for both prednisone and prednisolone were 2.1 µ g/L (signal-tonoise ratio no less than 3) and 7 µg/L (signal-to-noise ratio no less than I 0) respectively
(54). For prednisolone, there were 60 (12.7%) and 45 (9.1%) concentration values
below the LLQ and LLD respectively. For prednisone, there were 147 (29.6%) and 74
(14.9%) concentration values below the LLQ and LLD respectively. Because we were
able to address the residual error associated with low concentration values in our model,
we used all concentration values regardless of whether they were below the LLQ or LLD
(55 ;56).
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Data Preparation and Pharmacokinetic Analysis. Demographic, plasma collection
time, primary diagnosis ofreason for transplant, type of transplant, concomitant
medication, plasma concentration, laboratory examination, and dosing history data
relevant to the pharmacokinetic analysis were provided in Microsoft Excel (Excel 2000)
spreadsheets. For covariates that were not evaluated every day, values were carried
forward in time for that covariate until a new measurement was taken. Two patients had
an outlier value for one covariate. The outlier was changed to the last known value for
that patient. Thus, on day 20, patient #8 had a cystatin C value changed from I 0.9 to
1.46. On day 70, patient #69, had a bilirubin value changed from 210 to 10. Creatinine
clearance was calculated (using the Cockcroft-Gault formula) for each record as:

Males:

l .23·(140-age)weight (kg)/serurn creatinine (µmol/L)

Females:

1.04· (140-age)weight (kg)/serurn creatinine (µmoVL) (57).

Prednisolone has a reported half-life of2.3-3.5 hours (4). Since it was not possible to
ascertain that steady state bad been achieved, the dosing history for the five days prior to
an observed concentration record was included in the database. A covariate, "dose",
was generated to represent the dose that a patient was taking in relation to their
corresponding plasma concentrations at hours 0, 2, and 6 post dose.

Total prednisolone concentrations were assayed in this study. The unbound fraction was
estimated based on patients' albumin concentrations and a published algorithm, which
included values for transcortin and albumin binding capacities and affinity constants
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(9;24;3 l ). The first step was to convert the total prednisolone concentrations (ng/ml) to
molar concentrations using a molecular weight of360.4 for prednisolone (21). The
values used for the binding capacity (N,P,) and affinity constant (Kt) for transcortin were
5.69xl0-7M and 3.0lxl0 7 UM respectively (24). The values used for the albumin
binding capacity (N.P.) were calculated for each patient using their molar albumin
concentrations (molecular weight of albumin=66,300) (18). The value used for the
affinity constant (K.) for albumin was 2 .05xl03 LIM (24). Again, assuming that
K.Di<<l, there is one prednisolone binding site per molecule of albumin (N.= l ), and that
prednisolone only binds to transcortin and albumin(23;24;28;29), excel solver can be
used to solve for Dr in the following equation:

O= Di _ N1PK1D1 _ p al(alJi _Di
(l+JGDt)
where D, = total prednisolone concentration and DF unbound prednisolone
concentration (16). The unbound fraction (fu) was then calculated as:

fu=Df
Dt
Unbound prednisolone plasma concentration (ng/ml) was then calculated as:
Cp unbound prednisolone= Cp total prednisolone·fu.

The AUC for total prednisolone, unbound prednisolone, and total prednisone were
determined by the trapezoidal rule (58).
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The pharmacokinetic analysis was performed using NONiinear Mixed Effect Model
(NONMEM) version 5 level I. I double precision on a Pentium IV computer with a
Visual Fortran 5.0 compiler (59-62). NONMEM was run using PDx-Pop (v. 1. 1) (63)

Data Analysis Strategy.
An approach proposed by Mandema, et.al. (1992) (64) was used for the data analysis:
1) a base model was developed for the population, 2) the estimates found during step 1
were used to explore potential covariates with the base mode~ and 3) a mixed effects
model was developed to describe the relationship between the covariates and
pharmacokinetic parameters.

Pharmacokinetic and statistical models were evaluated to determine the model that best
fit the model dataset. To discriminate between models, the following criteria were used:
1) a decrease in the objective function value (which is proportional to minus twice the
log-likelihood of the data) of3.84

(i distribution, df=l, p< 0.05) or greater following

the addition of a single parameter was deemed statistically significant; 2) diagnostic plots
(e.g. predicted concentration versus observed concentration data, predicted
concentrations overlaying' all concentration data, weighted residuals versus predicted
concentration values), 3) minimization of variances: reduction ofinterindividual
variances and residual variability, and 4) the Akaike Information Criterion (AIC) (65;66).
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Prednisolone Phannacokinetic Base Model
Initially, a population base model was developed using only the prednisolone data. A
one compartment model with first order absorption was used to fit the unbound
prednisolone concentration data in order to determine prednisolone's pharmacokinetic
parameters prior to the inclusion of the metabolite (prednisone) data. There were not
enough concentrations captured during the absorption phase to adequately model the
absorption rate constant (k.). Instead, k. was determined by using a range of values and
finding which model had the lowest objective function value. The range of values fork.
was found by using Excel solver to solve fork. based on the following equation:

kn
log(- )

T m"'

= 2.303 • _ _k_
(lea- k)

where T max= time at which the peak concentration occurs, k.= absorption rate constant,
and k= the elimination rate constant (57) The elimination rate constant, k, can be
represented as:
k=0.693/t112
where t 112= prednisolone's half-life (57).

Based on literature values, the Tmax and half-

life ranges for prednisolone are 1-2 and 1.8-3.41 hours respectively (4;11;24;28). A
range of absorption rate constants were determined by using combinations of the
minimum and maximum Tmax and half-life values. Models were generated using each
absorption rate constant. The model that produced the smallest objective function value
was determined to be the best fit: a one-compartment model with a first-order
absorption rate of2.84 hr"' . The one-compartment model was parameterized as oral
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clearance (CL/F), apparent volume of distribution 01IF), and the first-order absorption
rate constant (k.) (NONMEM subroutines ADV AN2 TRANS2).

Analysis of Covariates with Prednisolone Base Model
Once the base prednisolone phannacokinetic model was obtained, the posthoc Bayesian
estimation (FO method) was implemented to obtain the individual parameter estimates to
evaluate potential influences of covariates. An exponential error model for interindividual
variability and a combined additive and proportional error model for the residual
variability were initially assumed for the covariate analysis. For pharmacokinetic
parameters CLIF and V/F, the potential influence of covariates on the individual
pharmacokinetic parameter estimates were evaluated. Age, weight, and time post
transplant were treated as continuous variables. Type of transplant was treated as a
categorical variable (O=single lung transplant, 1=double lung and heart transplant,
2=double lung transplant). Gender was treated as an indicator variable (O=female,
I =male). A concomitant medication was considered as present (O= not present,
I =present) if it was taken at any point within five days or on the same day as a
concentration value. The following concomitant medications were evaluated as
covariates: flucloxacillin, cefotaxime, ceftazidime, imipenem, ciprofloxacin, acyclovir,
ganciclovir, amphotericin, itraconazole, lyposomal amphotericin, and septrin. The
presence of cystic fibrosis was evaluated as a categorical covariate (O=not present,
I =present). Because menopausal status was not collected in this study, a variable was
created that was a marker for women over and under the age of fifty with O=under 50
and I =over fifty.

Creatinine clearance and cystatin C were evaluated as continuous
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covariates and included in the model as markers for renal function. Creatinine clearance,
cystatin C, time post transplant, and all concomitant medications were only evaluated on

CUF. Cortisol was evaluated as a continuous variable and was only evaluated on VIF.
All other covariates were evaluated on both CLIF and VIF.

Each covariate was added individually to the base model If the inclusion of the
covariate caused a decrease of the objective function value of at least 3.84, the covariate
was deemed as being statistically significant. Covariates that were found to be
statistically significant from the initial screening were then added simultaneously to the
base model to generate the full model A backward elimination procedure was then
performed on the full model. Each covariate was removed one at a time from the full
model. If the objective function value decreased by a more conservative value of7.88

Ci distribution, df=l , p< 0.005), the parameter was included in the final model.
Prednisolone and Predoisone Pharmacokinetic Base Model
The prednisone and prednisolone concentration data was simultaneously modeled. The
values for both VIF terms (VPIF=apparent volume of distribution for prednisolone and
VM/F=apparent volume of distribution for prednisone) were fixed and therefore not
estimated. Since there were no statistically significant covariates found on VIF in the
covariate analysis, VPIF was fixed to the population average value determined in the
prednisolone base model based on unbound prednisolone concentrations (VP/F=420 L).
VM/F was fixed at 55 L based on literature values (39). There were a total of four
possible elimination processes that could be modeled: clearance of prednisolone that is
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not metabolized to prednisone (CPR), clearance of prednisolone that is metabolized to
prednisone (CPM), clearance of prednisone that is reconverted to prednisolone (CMM),
and clearance ofprednisone that is not reconverted to prednisolone (CMR). Model I
modeled all four rates simultaneously (Figure 2). Because of the difficulty in modeling

all four rates, several simplified versions of Model 1 were used: Models 2-8 (Figures 39). A summary of the model variations follow.

Model 1: All four elimination terms are included linearly in the model (Figure 2)
Model 1 was a complete model ofprednisolone and prednisone, modeling all four
elimination processes. CPR, CPM, CMM, and CMR were included in the model
linearly. This model was structurally unstable; it was not possible to obtain estimates for
any of the individual clearances. There was not enough prednisone information for the
software to distinguish between the four elimination processes.

Model 2: No reconversion of prednisone to prednisolone (Figure 3)
Model 2 was a subset of Model 1; one elimination pathway was removed from Model I .
The reconversion ofprednisone to prednisolone (CMM) was removed. In this model, all
other elimination pathways (i.e. CPR, CPM, and CMR) were modeled linearly. It was
thought that by removing the interconversion, a simpler model might provide insight to
the pharmacokinetics of prednisone.
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Model 3: Removal of the reconversion of prednisone to prednisolone and the
elimination of prednisolone by pathways other than metabolism to prednisone
(Figure 4)
Model 3 was a subset of Model 2; one of the elimination pathways from Model 2 was
removed. It was assumed prednisolone was not metabolized to prednisone (CPR=O).
The conversion ofprednisone to prednisolone was removed from the model; thus all
prednisolone was converted to the metabolite prednisone (CPM) and then eliminated by
means other than reconversion to prednisolone (CMR). CPM and CMR were modeled
linearly. This model was attempted to see the effect of forcing all prednisolone to be
metabolized to prednisone.

Model 4: All prednisone was reconverted to prednisolone (Figure S)
Model 4 was a subset of Model I. The clearance of prednisone along pathways other
than reconversion to prednisolone (CMR) was set to zero. In this model, all other
elimination processes (i.e. CPR, CPM, and CMM) were modeled linearly. This model
was attempted because the clearance of prednisone is thought to be much smaller than
the other clearance processes (11).

Model 5: Relative value of the interconversion clearances were fixed (Figure 6)
Model 5 was a subset of Model 4 . The reconversion ofprednisone to prednisolone
(CMM) has been reported to be I 0 times the rate of conversion of prednisolone to
prednisone (CPM) (11). CMM was fixed at IO times the rate ofCPM. CPR and CPM
were modeled linearly.
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Model 6: Nonlinear metabolism of prednisolone to prednisone (Figure 7)
Model 6 was a subset of Model 4. The conversion of prednisolone to prednisone was
treated as a Michaelis-Menton process. CMM and CPR were modeled linearly. It has
been proposed that the conversion of prednisolone to prednisone follows a non-linear
process, so this model explores the possibility of CPM being nonlinear (2;24 ).

Model 7: Nonlinear reconversion of prednisone to prednisolone (Figure 8)
Model 7 was a subset of Model 4. The conversion of prednisone to prednisolone was
treated as a Michaelis-Menton process. CPM and CPR were modeled linearly. It has
been proposed that the reconversion of prednisone to prednisolone may follow a nonlinear process, so this model explores the possibility of CMM being nonlinear (2;24 ).

Model 8: Nonlinear elimination of all prednisolone not metabolized to prednisone
Model 8 was a subset of Model 4. Prednisolone that was not metabolized to prednisone
(CPR) was modeled as a Michaelis-Menton process. In this model, the conversion and
reconversion ofprednisolone and prednisone (CPM and CMM respectively) were
modeled linearly.

It has been proposed that the renal clearance of prednisolone may

follow a non-linear process, so this model explores the possibility of CPR being nonlinear
(24).
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Statistical Model

An exponential-error model was used to describe the interindividual variability of the
pharmacokinetic parameters. For example:
Exponential model: ®j=TV®*EXP(TJ;.e)
where 11;.e is a random variable distributed with a zero mean and variance of ro

2

9

and

TV® is the population mean value for® .

Residual variability was modeled separately for prednisolone and prednisone using an
additive and proportional-error model:
C,i=~_,/( I +i:"j) + &2ii

where Cii is the observed plasma concentration value for the jth individual at time=i,
~.ii

is the model predicted plasma concentration for the jth individual at time=i, &Iii is a

randomly distributed variable with a zero mean and variance of cr21, and &2;i is a randomly
distributed variable with a zero mean and variance of cr22.

RESULTS
Prednisolone and Prednisone Plasma Concentration-Time Data:
The fraction of unbound prednisolone at the various total prednisolone concentrations
was estimated using a patient's specific albumin concentrations. The results are shown
in Figure I 0. The calculated fraction of unbound prednisolone follows an expected
curve for saturable protein binding.
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Figures 11 and 12 show the observed plasma concentration time data for total and
unbound prednisolone respectively. In Figure 13, the total prednisone curve shows that
prednisone has a slower elimination since the slope is much shallower between the 2 and
6 hour post dose values than the slope seen in the prednisolone plots. The dose
normalized AUC of total prednisolone and unbound prednisolone were plotted versus
dose in Figures 14 and 15 respectively. The AUC of total prednisone normalized by
prednisolone dose versus dose was plotted in Figure 16. A negative slope was seen for
the dose normalized AUC of total prednisolone and total prednisone when plotted versus
dose (Figures 14 and 16). A slope of zero was seen for the dose normalized AUC of
unbound prednisolone versus dose (Figure 15). The AUC total prednisolone/ AUC
prednisone and AUC unbound prednisolone/AUC prednisone versus dose were plotted
in Figures 17 and 18 respectively. There was a negative slope when AUC total
prednisolone/AUC prednisone was plotted versus dose, and a positive slope when AUC
unbound prednisolone/AUC prednisone was plotted versus dose. The AUC unbound
prednisolone/AUC prednisone versus AUC unbound prednisolone/AUC total
prednisolone was plotted and exhibited a positive slope (Figure 19).

Prednisolone Model:
The plasma prednisolone concentration time data was best described using a onecompartment model with a first-order absorption rate of2.84 hr·'. lnterindividual
variability was described with exponential error terms for CL/F and V IF. Residual
variability was described with a combined additive and proportional-error model.
Originally, a base model was developed using total prednisolone concentrations. The
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observed versus predicted total prednisolone plasma concentrations have a wide spread
around the line of identity (Figure 20). The weighted residuals versus the predicted total
prednisolone concentrations have a negative trend. The smaller concentrations are
underpredicted while the larger concentrations are overpredicted (Figure 21). When the
unbound prednisolone concentrations were modeled, the diagnostic plots showed a
better fit. As a result, all further analyses were conducted on unbound prednisolone
concentrations.

Results from the unbound prednisolone concentration analysis are shown in Figures 2223 and Table 4. In Figure 22, observed unbound prednisolone concentrations were more
clustered around the line of identity though still underpredicted. The weighted residual
plot showed that larger values of predicted unbound prednisolone concentrations are no
longer overpredicted, but the smaller concentrations still had large variability (Figure
23). The base model results for the unbound prednisolone dataset are given in Table 4.
CL/F and V/F were found to be 17.2 L/h (0.302 L/h/kg) and 416 L (7.298 L/kg)
respectively.

Analysis of Covariates with Prednisolonc Base Model
Table 5 summarizes the effect of the individual addition of each covariate for CL!F and
V/F. Sex, ciprofloxacin, septrin, amphotericin, imipenem, and cystic fibrosis were found
to be statistically significant when included individually in the base model for CL/F. No
statistically significant covariates for VfF were identified. Additionally, cefotaxime,
albumin, age, type of transplant, flucloxacillin, acyclovir, dose, and creatinine clearance
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on CL/F and albumin, age, dose, and sex for V IF had significant changes in the objective
function value. While these covariates did have objective function value changes >3.84,
the 95% confidence interval for the covariate parameter estimate included the null value
and therefore the covariates were not considered in further model development. Time
post transplant was evaluated differently than the other covariates. Each occasion for
each patient was treated as having been a separate patient. CL/F was calculated at each
occasion and then normalized to that patient's first CL/F value (i.e. change in CLIF from
baseline). The normalized clearance was plotted versus time post transplant (Figure 24).
No trends were seen in the normalized clearance data; time post transplant was
determined to be insignificant. At-test assuming equal variances for independent
samples was also performed to further evaluate itraconazole use. There was no
statistical difference seen between the mean dose normalized unbound AUC of
prednisolone between itraconazole and non-itraconazole users.

All significant covariates were then combined to make the full model, which consisted of
sex, ciprofloxacin, septrin, amphotericin, imipenem, and cystic fibrosis as covariates for
CL/F. Backwards elimination was then performed to generate a reduced model.
Because there is a limit to the number of characters that can be used in a single line of
Fortran code, the backwards elimination analysis was done in 2 steps. Each covariate
was removed individually from the first full model (sex, ciprofloxacin, septrin, and
amphotericin for CL/F). A covariate was retained in the reduced model if there was a
significant decrease in the goodness of fit (i.e., objective function value decreased by
7.88

<i distribution, df=l , p< 0.005).

Following the first backwards elimination
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procedure, only sex and ciprofloxacin were identified as significant covariates for CUF.
The second full model consisted of sex, ciprofloxacin, imipenem, and cystic fibrosis as
covariates for CLIF. Again, backwards elimination was performed in the same manner
to generate the final model. Following the second backwards elimination procedure,
only sex and ciprofloxacin were identified as significant covariates for CLIF in the final
model (Table 6).

Table 7 summarizes the final model results for the unbound prednisolone concentration
data. Interindividual variability was best described with exponential error terms for CUF
and VIF. Residual variability was described with a combined additive and proportionalerror model. For the final model, lower values were obtained for the %RSE base
estimates for CLIF and V IF compared to the base model ( 14.1 vs 15.9% and 11.1 vs.
2

2

14.7% respectively) and the variability estimates, m cUF, m v/F,

a2 1, and a2 2

(0.020 vs.

0.313, 0. 109 vs. 0.390, 0.580 vs. 0.697, and 73.5 vs. 79.5 respectively). The variability
2

of the interinclividual variability estimates for m cUF and ro\IF were higher for the final
model as compared to the base model (135 .0 vs. 37.4% and 58.7 vs. 36.7%
respectively). Parameter estimate ranges were as follows: CL/F=7-73 L/h and
VIF= 135-415 L. The observed versus predicted plasma unbound prednisolone
concentrations and weighted residual versus predicted plasma unbound prednisolone
concentrations were plotted in Figures 25 and 26 respectively. In Figure 25 , the
observed unbound prednisolone concentrations were better predicted as seen by more of
a spread around the line of identity. The model still had difficulty predicting the large
unbound prednisolone concentrations (Figure 26).
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Prednisolone and Prednisone Pharmacokinetic Base Model
As explained in the Methods, a pharmacokinetic model for prednisolone and its
metabolite, prednisone was developed based on the pharmacokinetic characteristics of
these species (Figure 2). Since the amount of prednisone formed from prednisolone was
unknown it was not possible to use this complete model. Several simplified versions of
the complete model were evaluated as described below.

Model 2: No reconversion ofprednisone to prednisolone (Figure 3)
In this model, the reconversion of prednisone to prednisolone (CMM) was ignored. All
other elimination processes, the clearance of prednisolone not metabolized to prednisone
(CPR), the clearance of prednisolone metabolized to prednisone (CPM), and the
clearance of prednisone not reconverted to prednisolone (CMR) were modeled linearly.
This model was highly dependent on initial estimates and structurally unstable. With one
set of initial estimates, the clearance of prednisolone was pushed through processes not
involving prednisone. Thus CPM and CMR were very small. When the initial estimates
were slightly changed, the model "flipped" and virtually all prednisolone was then
eliminated through metabolism to prednisone (CPM).

Model 3: Removal of the reconversion of prednisone to prednisolone and the
elimination of prednisolone by pathways other than metabolism to prednisone
(Figure 4)
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In this model, all of the prednisolone was assumed to be metabolized to prednisone
(CPM). All elimination processes were modeled linearly. This model proved to be
structurally sound, but is not in agreement with the known pharmacokinetic
characteristics of the drug. A recycled fraction of0.76 has been reported for the
interconversion ofprednisolone and prednisone and urine recovery of unchanged
prednisolone bas been reported at approximately 20% (11 ).

Model 4: All prednisone was reconverted to prednisolone (Figure S)
In this model the clearance of prednisone by pathways other than reconversion to
prednisolone was removed from the model. Thus all prednisone was reconverted back
to prednisolone. All other elimination processes (i.e. CPR, CPM, and CMM) were
modeled linearly. This model provided equivalent values for CPM and CMM.
Essentially, the model was unable to distinguish between these clearances. The model
was unable to account for the interconversion of prednisolone and prednisone.

Model S: Relative value of the interconversion clearances were fixed (Figure 6)
According to the literature, CMM is estimated to be about I 0 times CPM ( 11 ). Thus in
this model, CPM was estimated but CMM was fixed to IO times the value ofCPM. All
processes were modeled linearly. This model did not adequately describe the metabolite
data as seen in diagnostic plots (Figure 27). The predicted prednisone concentration
values were not distributed around the line of identity and were underpredicted.
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The plots with the AUC for total prednisone indicated that their nonlinearity might be
associated with the interconversion of prednisolone and prednisone (Figures 16-19).
Models 6 and 7 were attempted to address these concerns. In Models 6 and 7, the
clearance of prednisone was assumed to occur only through its reconversion to
prednisolone (i.e. CMR was set to zero).

Model 6: Nonlinear metabolism of prednisolone to prednisone (Figure 7)
The conversion of prednisolone to prednisone was assumed to follow Michaelis-Menton
kinetics. This model was structurally unstable and it was not possible to obtain estimates
for CPR.

Model 7: Nonlinear reconversion of prednisone to prednisolone (Figure 8)
The reconversion ofprednisone to prednisolone was modeled using Michaelis-Menton
kinetics. This model was structurally unstable. Estimates were obtained for the two
prednisolone clearances (CPR and CPM). Initially, the model was able to obtain the
Michaelis-Menton estimates for the reconversion of prednisone to prednisolone, but
again these estimates were highly sensitive to the initial estimates.

Model 8: Nonlinear elimination of all prednisolone not metabolized to prednisone
(Figure 9)
In this model, the clearance of prednisolone, by processes other than metabolism to
prednisone, was modeled as a nonlinear process. The conversion and reconversion of
prednisolone and prednisone (CPM and CMM respectively) were modeled linearly.
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This model was structurally unstable. This model bad equivalent values for CPM and
CMM. Essentially, the model was unable to distinguish between these elimination
processes.

DISCUSSION
The study demonstrated that a population pharmacokinetic modeling approach could be
used to model prednisolone concentration-time data from a thoracic organ transplant
clinical trial. Additionally, the study demonstrated that it was possible to identify
covariates to explain variability in the pharmacokinetic parameters. Sex and
ciprotloxacin were found to be significant covariates for CL/F. It was not possible to
model prednisolone and prednisone concentration-time data simultaneously.

The data used for this study consisted of total prednisolone concentrations. A negative
slope in the dose normalized AUC of total prednisolone versus dose was observed
(Figure 14); as dose increased the dose normalized AUC decreased. If total
prednisolone concentrations exhibited linear pharmacokinetics, the slope of Figure 14
would have been zero (CL=F·Dose/AUC). The negative trend could be explained by
one of two reasons; either CL increased with dose or F decreased with dose. Previous
studies have suggested that the nonlinearity in prednisolone's pharmacokinetics is due to
saturable protein binding. Furthermore Rose et.al. (24)developed a model for the protein
binding of prednisolone based on prednisolone concentration, albumin concentration and
transcortin levels. This model was used to estimate the unbound prednisolone
concentrations associated with each total prednisolone concentration for this analysis. In
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the model for this analysis, the albumin binding capacity (N.P.) was calculated for each
patient using their molar albumin concentrations, while the affinity constant (K.) for
3

albumin was set at 2.0Sxl0 LIM based on the values obtained in the Rose et.al. paper
(24). Since transcortin concentrations were not available for the patients in the study,
the Rose et. al. values for the transcortin binding capacity (N 1P1) and affinity constant (K,)
7

7

were used (S .69xl0- M and 3.0lxl0 LIM respectively) (24). Using a population value
for the transcortin concentration levels may have introduced bias into the calculation of
unbound prednisolone. However, a plot of the dose normalized AUC of unbound
prednisolone versus dose had a slope approaching zero (Figure IS), which indicated the
pharrnacokinetics of unbound prednisolone were linear.

Base models were generated for both total and estimated unbound prednisolone
concentrations. In addition to the nonlinearity seen in Figure 14, it appeared that the
base model using total prednisolone concentrations was nonlinear based on the negative
slope seen in the weighted residuals plot (Figure 21 ). As a result all subsequent analyses
were conducted on the estimates unbound prednisolone concentrations. For the
unbound prednisolone concentrations, CUF and V/F were approximately 0.302 Lib/kg
and 7.298 L/kg respectively (mean weight=S7 kg). Two previous studies with a control
cohort of healthy volunteers found unbound prednisolone CUF and V/F values ranging
from 0.666-0.694 L/h/kg and 1.340-1 .610 L/kg respectively (Table 1) (27;30). In
studies with kidney transplant patients taking concomitant cyclosporine, total and
unbound prednisolone CL/F values ranged from 0.075 -0.140 and 0.492-0.S IO L/h/kg
respectively (Table I) (38;67-70). In this same population, the total and unbound
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prednisolone V IF values ranged from 0.680-0.720 and 1.480-1.600 L/kg (Table 1)
(38;70). In studies with kidney transplant patients not taking concomitant cyclosporine,
total and unbound prednisolone CL/F values ranged from 0.045-0.171 and 0.315-0.886
L/h/kg respectively (Table 1) (1;15;38;67;68;70;71). These patients had total and
unbound prednisolone V IF values ranging from 0.224-0. 780 and 1.460-2. 100 L/kg
respectively (Table 1) (1;38;70;71). The unbound prednisolone CLIF value of0.302
L/h/kg found in the present study compares favorably to both the transplant patients
taking cyclosporine (0.492-0.510 L/h/kg) and those transplant patients not taking
concomitant cyclosporine (0.315-0.886 L/h/kg). There is some debate as to whether
cyclosporine inhibits the metabolism of prednisolone (38;67;68;70). It has been
suggested that cyclosporine is an inhibitor of CYP3A4 (72), though references as to the
mechanisms of the inhibition have not been found in a literature search(73). In two
separate studies, Ost and Langhoff et.al. found that patients taking concomitant
cyclosporine had lower total prednisolone clearances than those patients taking
concomitant azathioprine (67;68). Frey et.al. found no differences between concomitant
cyclosporine and azathioprine users in total or unbound prednisolone clearances (38).
Rocci et.al. found that concomitant cyclosporine use did not affect the total or unbound
prednisolone clearances (70). Both Frey et.al. and Rocci et.al. attributed their different
results to the fact that they measured unbound prednisolone concentrations, conducted
repeated measurements over a longer interval, and used both intravenous prednisolone
and oral prednisone to eliminate confounding from the interconversion process (38;70).
The CLIF values found in the present analysis were about 50% of the healthy volunteers
and the unbound prednisolone VIF value of7.298 L/kg were considerably larger than the
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reported values for cyclosporine and non-cyclosporine users (1.480-1.600 and 1.4602.100 Ukg respectively), and about five times larger than the healthy volunteers. There
was difficulty in estimating VIF in the present study. Data was only collected at
approximately three time points for all patients (0, 2, and 6 hours post dose). Thus, a
complete concentration-time profile for the entire population was not captured.
Furthermore, owing to the paucity of information in the early period following the dose,
assessment of both volume of distribution and

k. were extremely difficult. The k. was

fixed in this study.

In the present analysis, the values for unbound prednisolone oral clearance for males
(n=23) and females (n=l8) were 1.216 Lib/kg and 0.240 L/h/kg respectively; males had
a significantly larger clearance than females. There have been three reported studies that
have found sex as a statistically significant covariate for prednisolone CL/F (Table 1)
(40;43;44). Meffi.n et.al. and Frey et.al. reported that males had a significantly smaller
unbound prednisolone clearance than females (Table 1) (40;43). In both of these studies,
a small number of subjects were dosed with intravenous prednisolone (Meffi.n: four
males, four females; Frey: eight males, six females). In a different study using oral
prednisone, Magee et. al. found opposite results; males had a significantly larger (20%)
unbound prednisolone oral clearance than females (44). Magee's study had a larger
number of subjects (Magee: sixteen males, sixteen females) . Additionally, Magee's study
controlled for menstrual cycle phase by having each female begin the study at the same
point in their menstrual cycle (44). Magee el.al. suggested that the reasons for their
different results from Meffi.n et.al. and Frey et.al. may be attributed to their larger sample
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size, different formulation, and that they controlled for the timing of the female menstrual
cycle, which made it easier to identify a gender effect. Both CL/F and V IF were smaller
in female subjects, implying that women may have a larger bioavailability of prednisone
relative to men (44). The present analysis had a similar sample size (23 males; 18
females) to the Magee study. The inability to identify a gender effect for VIF in the
present study could be a function of the lack of informative data to adequately estimate
V IF. In the present analysis oral contraceptive usage, menstrual cycle phase, and
menopause status were not collected. Oral contraceptive usage has been reported to
reduce unbound prednisolone clearance (2;4;15;22;27;29;30;38;46). The unbound
prednisolone clearance value of0.240 L/h/kg for females in this study was lower than the
0.467-0.540 L/h/kg values reported elsewhere (Table 1) (27;30). Postmenopausal
women reportedly have lower unbound prednisolone clearances than premenopausal
women by around 30% (Table 1) (34). Since oral contraceptive use and menopause
status was not captured in this study, its effect was unknown.

It has been suggested that young women have approximately 1.4 times the CYP3A4
activity of men (74). Thus, it would be anticipated that females might exhibit larger
clearances in CYP3A4 substrate drugs than males. The role, if any, ofCYP3A4 in
prednisolone elimination is not clear. While some authors have found little effects of
CYP3A4 inhibitors on prednisolone clearance (34;36;48 ;49), another study found total
and unbound prednisolone clearances decreased with ketoconazole (13). In the present
study, itraconazole was not found to reduce the clearance of unbound prednisolone.
However, it is possible that the study did not have sufficient statistical power to

129

adequately probe the effects of itraconazole. Only seven subjects were talcing
itraconazole at some point during the study period and these seven subjects provided a
total of only fifteen samples during concomitant itraconazole use.

Concomitant ciprofloxacin was also identified as a significant covariate for CL/F;
ciprofloxacin use reduced the unbound prednisolone oral clearance (by 48% and I 0% in
females and males respectively). Unbound clearance values for patients using
ciprofloxacin were 0.125 L/h/kg and I.JOO L/h/kg for females and males respectively.
Ciprofloxacin is a known inhibitor ofCYPIA2 and CYP3A4 activity (75-77). A
literature search found no reports of interaction studies for prednisolone and CYP I A2
inhibitors. The results from the present study suggest that CYP I A2 may be a pathway
for prednisolone metabolism and that CYPIA2 interaction studies may be warranted.

Other studies have reported that that cystic fibrosis patients have increased total
prednisolone clearances (50). In the present study cystic fibrosis was not a significant
covariate for CL/Fin the final model. However, all of the cystic fibrosis patients (n=6)
were male. Thus, it may be impossible to separate the effects of cystic fibrosis and
gender in this data set. It is also possible that effects of cystic fibrosis may have elevated
the estimates for CL/F in males in the present study. It is interesting to note that the
weight normalized values of CL/F tended to be larger in the male cystic fibrosis patients
compared to the other male patients (Figure 28).
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It proved to be challenging to model prednisolone and prednisone simultaneously. When
a complete model that included all elimination processes was used, the model was
structurally unstable (Model 1; Figure 2). The amount of prednisone formed from
prednisolone was unknown; consequently the estimates of the parameters used in this
model were highly unstable. Many variations of Model 1 were used (Models 2-8;
Figures 3-9) but they were either structurally unstable or did not adequately describe the
data. It is believed that part of the difficulty in modeling the data was due to previously
noted nonlinearity in the pharmacokinetics of prednisolone and prednisone. Figure 16
showed that the AUC of total prednisone normalized by prednisolone dose decreased
with increasing dose (negative slope), indicating the presence of nonlinear
pharmacokinetics. If all clearances of prednisolone had been equally affected by protein
binding, increasing the dose ofprednisolone simply would have produced a proportional
increase in the conversion of prednisone. Assuming linear pharmacokinetics of
prednisone, this scenario would have produced a slope of zero in Figure 16.
Alternatively, if the conversion ofprednisolone to prednisone was more sensitive to
protein binding than the other clearances, then as the dose of prednisolone increased, the
fraction converted to prednisone would have increased disproportionally. Again
assuming linear pharmacokinetics of prednisone, a positive slope would have been
expected in Figure 16. Instead, the relationship seen (negative slope) could occur
through two possible mechanisms: the conversion of prednisolone to prednisone may be
a saturable process and/or the elimination of prednisone may be nonlinear. The reason
for the saturable metabolism of the conversion ofprednisolone to prednisone is
unknown, though it has been proposed that it may be attributable in part to a saturation
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of 11-~-hydroxydehydrogenase, the enzyme responsible for the interconversion of
prednisolone to prednisone (I 0;20). Nonlinearity with prednisone was noted in Figure
18. AUC total prednisolone/AUC prednisone versus dose produced a negative slope
(Figure 17). When correcting for prednisolone's nonlinearity by using unbound
prednisolone concentrations instead of total prednisolone concentrations, AUC unbound
prednisolone/AUC prednisone versus dose produced a positive slope (Figure 18).
Knowing that unbound prednisolone exhibited linear pharrnacokinetics, it was the
nonlinearity of total prednisone driving the increase in slope on this plot.

The concentration-dependent binding of prednisolone may affect the interconversion
process. If the interconversion ofprednisone and prednisolone depended solely on the
concentration of unbound prednisolone, the ratio of unbound prednisolone to prednisone
would remain constant, regardless of the unbound fraction ofprednisolone in plasma
(slope=zero ). Instead, a positive slope was seen in Figure 19; interconversion is not
so lely dependent on protein binding, other factors (e.g enzyme inhibition) must influence
the interconversion process (24).

In order to model prednisolone and prednisone concentration time data simultaneously,
future clinical trials should be designed to address some of the issues encountered in this
analysis. More concentration values are needed during the absorption time period
(specifically concentration data in between the 0-2 hour post dose interval). The
additional data would have allowed one more parameter in this model to have been
estimated rather than fixed from literature values and would have permitted better
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estimation ofVfF. If unbound prednisolone concentrations are not measured directly in
patients, than both albumin and transcortin should be measured in order to permit a more
accurate estimation of the unbound fraction ofprednisolone. Information regarding oral
contraceptive usage, menstrual cycle phase, and menopause status would provide a
better understanding of the impact of these factors in the pharmacokinetics of
prednisolone. If possible, populations that are anticipated to have altered
phannacokinetics should be stratified to address potential confounders; in this trial, all
cystic fibrosis patients were male. Dosing patients with prednisone, in addition to
prednisolone, would enable the estimation of the pharmacokinetic parameters of
prednisone.

In conclusion, this study has shown that population phannacokinetic models could be
used to model prednisolone plasma concentration time data obtained in a thoracic organ
transplant population dosed with oral prednisolone. A one-compartment model with a
fixed first order rate of absorption was used to describe the unbound prednisolone
concentration versus time data. Sex and ciprofloxacin for CUF were found as
significant covariates. It was not possible to adequately model prednisolone and
prednisone concentration time data simultaneously. The results of this study may
provide help to better dose thoracic transplant patients with oral prednisolone.
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Table l. Summary of Prednisolone Pharmacokinetics in Various Populations
First Author
(Reference)
Stuck_{_l '!2_
Meffinl_4![
Frey (43)

Unbound
Total
CL
CL
J!,_/h/k_g}_ _{_L/h/k_g}_
0.400f
Elder_!y_
0.640
Youn_g_
--0.620f
Male
0.164!
0.752
Female
0.193
0.693l
Female - before 0.171t

Population

Total VD
(L/kg)

---

Unbound
VD

_i!./k_fil

---

---

---

0.669
0.676
0.650

1.546
l.543
1.690

_E_he~oin

0.248

0.103

0.620

l.590

0.148'

0.650

0.562f

l.550

0.210

0.640

0.839

l.540

0.178
0.172
0.181
0.165
0.169t
0.081
0.174T
0.096
o.11ot

0.788
0.778
0.644
0.554
0.6941
0.467
0.666t
0.540
0.8761

0.590
0.613
0.453
0.586
0.684r
0.550
0.640T
0.540
0.8181

2.180
2.183
l.650
l.580
1.340
l.290
1.610
l.710
2.770

0.550
----0.996t
0.696

0.605

l.840

-----

-----

0.580
0.430

2.520
1.790

TransplantAzathiOJJ!ine
Cushingoid

0.082
0.168t
0.139
0.1501
0.110
0.1100.140t
0.1500.160
0.160

Non-Cushingoid

0.150

Female - after
__£_he~oin

Frey (43)

Male- before
_l)hen.Y!_oin
Male- after
phenytoin
White Males
M~ee_{_4'!2_¥
Black Males
White Females
Black Females
Control
Meffin_Q Q2_
OC users
Control
Fr~71_
OC users
Boekenoogen Control*

__G~

Imani_f471_

:Q-!5:

Harris

OC users*
Control*
Diltiazem users*
Premeno~usal
Postrnen~ausal

Ost (67)

Transplant ~[OS]JOrine

Ost (1) - no
C}'ClOS]JOrine
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Gambertoglio
(71)-no

Transplant
Control

0.100

0.644

0.460

2.03

TransplantAnticonvulsant
Transplant -

o.111t

0.8861"

0.470

1.53

~los.I>Q_rine

Langhoff (68)

-0.114

~lo~rine

Bergrem (15)
-no

TransplantAzathiqp_rine
Cushingoid*

-0.144T
0.04.5f

0.27:31

0.229

---

Non-

0.051

0.315

0.224

---

0.140

0.492

0.680

1.480

0.132

0.499

0.610

1.460

0.160

0.620

0.780

2.100

Transplant 0.130
PostCy_closp_orine
Transplant - Pre 0.094
Sirolimus

0.510

0.720

1.600

~los.I>Q_rine
cushin~id*

Frey (38)

Rocci (70)

Transplant Cy_closp_orine
TransplantAzathiq£!ine
Transplant Pre_(::y_clo~ine

Jusko (69) with
~los.I>Q_rine

Transplant Post Sirolirnus

O.D75

• Mean weight of70kg used
t P-value <0.05 or smaller for the population comparison
¥ P-value <0.01 for comparison of gender. Race and gender by race comparisons were
not significant.
Abbreviations: VD=volume of distribution, CL=clearance, OC=oral contraceptive

147

Table 2. Characteristics of Thoracic Organ Transplant Patients Evaluated in the
Population Pharmacokinetic Analysis of Prednisolone
Characteristic
Total number ot:.£.atients
Male
Female
~_{year~
We~

41
23
18

42.9~ange=19-66l
57.0~an~37-8§:

T ransJ.>_lant type
Heart and lung
Double lun~
Sin_Eie lun__g_
::fistic fibrosis
A21.clovir
Amphotericin
Cefotaxime
Ceftazidime
C!J2!ofloxacin
Flucloxacillin
Ganciclovir

19
7
15
6
8
6
10

17
14
24
33
4
7
4
31

Imi~nem

ltraconazole
Lyp~sornal amphotericin
St!E_trin
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Table 3. Example of Partial Prednisolone Dosing History: Patient #4

Patient

4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4

Day Post
Transplant

0
J
2
3
4
5
6
7
8
9
10
IJ
J2

Total Daily
Oral
Prednisolone
Dose(mg)

0
50
45
40
35
30
25
20
J5
30
15

13

J4
J5
I6
J7
18
J9
20
2J
22
23
24
25
26
27
28
29
30
3J
32
33
34
35
36
37
38

50
50
40
35
30
25
20
J5
10
IO

60
55
50
45
40
35
30
25
20
I5
IO
JO

Prednisolone
a.m.
Dose (mg)

Prednisolone
p.m.
Dose(mg)

0
25
25

0
25
20
20
15
J5
JO
5
0
15
0
0
0
0
25
25

20

20
J5
J5
15
J5
15
J5
0
0
0
25
25
20
20
J5
J5
15
15
10
IO
0
0
0
30
30
25
25
20
20
J5
I5
J5
J5
JO
JO
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20

J5
15
JO
5
0
0
0
0
0
0
30
25
25
20
20
J5
I5
IO
5
0
0
0

Methylprednisolone
Dose (mg)

0
0
0
0
0
0
0
0
0
0
0
1000
1000
500
0
0
0
0
0
0
0
0
0
0
1000
500
500
0
0
0
0
0
0
0
0
0
0
0
0

Table 4. Base Model for the Pharmacokinetics Model of Prednisolone

Parameter
CLl(tLlh}=e,
V/Ffil= 82
e,
k.

_Ql:'.E

2
W c UF

W V/F

~

~

t

Estimated
Value
17.2
416
2.84[
0.313
0.390
0.697
79.5

%RSE
15.9
14.7
-37.4
36.7
22.8
50.8

95% Confidence
Interval
11.8,22.6
296,536
-0.084,0.542
0.110,0.670
0.385,1.010
0.3,159.0

k. was fixed at 2.84 h·'

Abbreviations: %RSE=percent relative standard error, CL/F = oral clearance, VIF= oral
volume of distribution, ka= first-order absorption rate constant, w2cUF =interpatient
variability ofCL/F, w2vlF = interpatient variability ofV/F, d', =variance of proportional
portion ofresidual error, d 2 =variance of additive portion of residual error.
A one compartment model with a fixed first order absorption rate constant
(k.=2.84 hr·'), exponential interindividual variability, and a combined proportional and
additive residual error were used.
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Table 5. Analysis oflndividual Covariates for Unbound Prednisolone Base Model
Objective
Change in Objective
Function Value
Covariate Anal_Eis
Function Value
Base Model - No covariates
3554.588
SexforCUF
3405.003
-149.585
Cefotaxirne for CLIF *
3487.214
-67.374
3490.455
Ciprofloxacin for CUF
-64.133
-42.367
Septrin for CUF
3512.221
3544.546
-30.991
Albumin for VIF *
Albumin for CLIF *
3525.231
-29.357
Amphotericin for CUF
3526.041
-28.547
lmipenem for CUF
3528.633
-25.955
3533.241
-21.347
Age for CLIF *
3540.647
Cystic fibrosis for CUF
-13.941
3541.016
-13.572
Type for CLIF *
3542.368
-12.220
Flucoxacillin for CLIF *
3543 .551
Acyclovir for CLIF *
-11.037
3545.029
Age for VIF •
-9.559
3546.328
-8.260
Dose for V /F *
Sex for V/F *
3546.738
-7.850
3547.350
Dose for CL/F *
-7.238
3547.753
-6.835
Creatinine clearance for CL/F *
Lyposornal arnphotericin for CLIF
3553 .567
-1.021
Type for VIF
3553.859
-0.729
3553.942
Weight for CLIF
-0.646
Weight for VIF
3554.257
-0.331
Cystic fibrosis for VIF
3554.343
-0.245
3554.588
Cystatin C for CLIF
0
ltraconazole for CL/F
3555.423
0.835
Ganciclovir for CLIF
3558.203
3.615
3636.749
Ceftazidirne for CLIF
82.161
Cortisol for VIF **
--Bold covariates were deemed statistically significant.
* 95% confidence interval of parameter estimate includes the nuU value.
** The addition of cortisol as a covariate in the base model caused model instability.
The diagnostic plots showed that cortisol did not add any further improvement in the fit
of the model and therefore was not included in any further model development.

---

Abbreviations: CLIF = oral clearance, V/F = oral volume of distribution, type=type of
transplant.
A one compartment model with a fixed first order absorption rate constant (k.=2.84 hr1), exponential interindividual variability, and a combined proportional and additive
residual error were used.
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Table 6. Backward Elimination for the Full Model of Unbound Prednisolone
Removed Covariate

Sex, ciprotloxacin, septrin,
amphotericin for CL/F
No covariate removed
Sex
Ciprotloxacin
Septrin
~otericin

Sex, ciprotloxacin, amphotericin
for CL/F
No covariate removed
Sex
Ciprotloxacin
~hotericin

Sex, ciprotloxacin, irnipenem,
cystic fibrosis for CL/F
No covariate removed
Sex
Ciprotloxacin
lmipenem
~tic fibrosis
Sex, ciprotloxacin, cystic fibrosis
for CL/F
No covariate removed
Sex
Ciprotloxacin
~tic fibrosis
Sex, ciprotloxacin for CL/F
No covariate removed
Sex
C~otloxacin

Objective
Function
Value

Change in
Objective
Function Value

p-Value

3439.156
3464.470
3445.645
3370.275
3469.252

-25.314
6.489
-68.881
30.096

-< 0.005
< 0.005
NS
< 0.005

3370.275
3466.281
3399.395
3376.170

-96.006
29.120
5.895

-< 0.005
< 0.005
NS

3365.838
3619.883
3376.681
3368.618
3375.064

-254.045
10.843
2.780
9.226

-< 0.005
< 0.005
NS
< 0.005

3368.618
3633. 179
3387.505
3376.167

-264.561
18.887
7.549

-< 0.005
< 0.005
NS

3376.167
3490.455
3405.003

-114.288
28.836

-< 0.005
< 0.005

Abbreviations: CL/F = oral clearance, NS=not significant.
A one compartment model with a fixed first order absorption rate constant (k.=2.84 hr1) , exponential interindividual variability, and a combined proportional and additive
residual error were used.
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Table 7. Final Model for Prednisolone Alone Dataset

Parameters
CL/F (L/h)=E> 1 +

E> 4·sex+

e,
e.
e,
V/F- (L)= E>2
k.J!Q=e,
olcUF
ffi2v/F

~

.!D

Estimated
Value

%RSE

95% Confidence
Intervals

13.7
55.6
-6.6
281
2.84_.i
0.020
0.109
0.580
73.5

14.1
11.6
29.8
I I.I

9.9,17.5
43.0,68.2
-10.5,-2.8
220,342

--

--

135
58.7
18.6
33 .7

-0.033,0.073
-0.016,0.234
0.368,0.792
24.9,122.0

0 5·cipr

t k. was fixed at 2.84 h"'
Abbreviations: %RSE=percent relative standard error, CL/F = oral clearance, V/F = oral
volume of distribution, ka= first-order absorption rate constant, w2 cUF =interpatient
variability ofCL/F, w2 v tF = interpatient variability ofV/F, cr2 1 =variance of proportional
portion of residual error, cr22 =variance ofadditional portion of residual error,
cipr=ciprofloxacin use.
Sex: O=female, I =male
Ciprofloxacin: O=no concomitant ciprofloxacin use, I =concomitant ciprofloxacin use
A one compartment model with a fixed first order absorption rate constant (k.=2.84 hr.
1
), exponential interindividual variability, and a combined proportional and additive
residual error were used.
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Figure I. Distribution of Percent(%) of Concentration Samples versus Prednisolone
Dose(mg)
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Figure 2.

Prednisolone (Parent) and Prednisone (Metabolite) Pharmacok:inetic Model

1: All four elimination terms are included linearly in the model

0

~

Prednisolone
(parent)

Prednisoae
(metabolite)

~

0

[]

I) Fixed first order absorption rate constant
2) Clearance of prednisolone that is not metabolized to prednisone = CPR
3) Clearance of prednisolone that is metabolized to prednisone = CPM
4) Clearance of prednisone that is reconverted to prednisolone =CMM
S) Clearance of prednisone that is not reconverted to prednisolone =CMR
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Figure 3.

Prednisolone (Parent) and Prednisone (Metabolite) Pbarmacokinetic Model

2: No reconversion of prednisone to prednisolone

.0
Prednisone

Prednisolone
(parent)

(metabolite)

I) Fixed first order absorption rate constant
2) Clearance of prednisolone tbat is not metabolized to prednisone = CPR
3) Clearance of prednisolone that is metabolized to prednisone = CPM
5) Clearance of prednisone that is not reconverted to prednisolone =CMR
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Figure 4.

Prednisolone (Parent) and Prednisone (Metabolite) Pharmacokinetic Model

3: Removal of the reconversion ofprednisone to prednisolone and the elimination of
prednisolone by pathways other than metabolism to prednisone

Prednisolone
(parent)

Prednisone
(metabolite)

I) Fixed first order absorption rate constant
3) Clearance of prednisolone that is metabolized to prednisone = CPM
5) Clearance of prednisone that is not reconverted to prednisolone =CMR
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Figure 5.

Prednisolone (Parent) and Prednisone (Metabolite) Pharrnacokinetic Model

4: All prednisone was reconverted to prednisolone

Prednisolooe
(parent)

Prednisone
(metabolite)

1) Fixed first order absorption rate constant
2) Clearance of prednisolone that is not metabolized to prednisone = CPR
3) Clearance of prednisolone that is metabolized to prednisone = CPM
4) Clearance ofprednisone that is reconverted to prednisolone =CMM
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Figure 6.

Prednisolone (Parent) and Prednisone (Metabolite) Pbarmacokinetic Model

5: Relative value of the interconversion clearances were fixed

Prednisolone
(parent)

Prednisone
(metabolite)
IO·Rate 3

1) Fixed first order absorption rate constant
2) Clearance of prednisolone that is not metabolized to prednisone = CPR
3) Clearance of prednisolone that is metabolized to prednisone = CPM
4) Clearance of prednisone that is reconverted to prednisolone =CMM fixed to be
lO·CPM
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Figure 7.

Preclnisolone (Parent) and Preclnisone (Metabolite) Pharmacokinetic Model

6: Nonlinear metabolism of preclnisolone to preclnisone

Prednisolone
(parent)

Prednisone
(metabolite)

I) Fixed first order absorption rate constant
2) Clearance of prednisolone that is not metabolized to prednisone =CPR
3) Clearance elimination of prednisolone that is metabolized to prednisone = CPM
4) Clearance of prednisone that is reconverted to preclnisolone =CMM

160

Figure 8.

Prednisolone (Parent) and Prednisone (Metabolite) Pharrnacokinetic Model

7: Nonlinear reconversion of prednisone to prednisolone

Prednisone
(metabolite)

Prednisolooe
(parent)

1) Fixed first order absorption rate constant
2) Clearance of prednisolone that is not metabolized to prednisone = CPR
3) Clearance of prednisolone that is metabolized to prednisone = CPM
4) Nonlinear clearance of prednisone that is converted to prednisolone =CMM
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Figure 9.

Prednisolone (Parent) and Prednisone (Metabolite) Pharmacokinetic Model

8: Nonlinear elimination of all prednisolone not metabolized to prednisone

Prednisolone
(parent)

Prednisone
(metabolite)

2-NL

I) Fixed first order absorption rate constant
2) Nonlinear clearance of prednisolone that is not metabolized to prednisone = CPR
3) Clearance of prednisolone that is metabolized to prednisone = CPM
4) Clearance of prednisone that is reconverted to prednisolone =CMM
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Figure I 0. Fraction of Unbound Prednisolone Concentration versus Total Prednisolone
Concentration (ng/ml} Individual Values for Albumin
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Figure 11 . Observed Total Prednisolone Concentration (ng/ml) versus Time Post Dose
(minutes)
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Figure 12. Observed Unbound Prednisolone Concentration (ng/ml) versus Time Post
Dose (minutes)
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Figure 13 . Observed Total Prednisone Concentration (ng/ml) versus Time Post Dose
(minutes)
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Figure 14. Dose Nonnalized AUC Total Prednisolone (ng*hr/ml/mg) versus Dose (mg)
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Figure 15. Dose Normalized AUC Unbound Prednisolone (ng*hr/ml/mg) versus Dose
(mg)
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Figure 16. AUC Total Prednisone (ng*hr/mVmg) Normalized by Prednisolone Dose
versus Dose (mg)
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Figure 17. AUC Total Prednisolone/AUC Total Prednisone versus Dose (mg)
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Figure 18. AUC Unbound Prednisolone/AUC Total Prednisone versus Dose (mg)
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Figure 19. AUC Unbound Prednisolone/AUC Total Prednisone versus AUC Unbound
Prednisolone/AUC Total Prednisolone
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Figure 20: Observed Prednisolone Plasma Concentration versus Predicted Prednisolone
Plasma Concentration Values for the Total Prednisolone Concentration Base Model
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A one compartment model with a fixed first order absorption rate constant (k,=2.84 hr1), exponential interindividual variability, and a combined proportional and additive
residual error were used .
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Figure 21 : Weighted Residuals versus Predicted Prednisolone Plasma Concentration
Values for the Total Prednisolone Concentration Base Model
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A one compartment model with a fixed first order absorption rate constant (k,,=2.84 hr1), exponential interindividual variability, and a combined proportional and additive
residual error were used .
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Figure 22. Observed Prednisolone Concentration versus Predicted Prednisolone
Concentration Values for the Unbound Prednisolone Base Model
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A one compartment model with a fixed first order absorption rate constant (k,=2.84 hr1), exponential interindividual variability, and a combined proportional and additive
residual error were used .
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Figure 23. Weighted Residuals versus Predicted Prednisolone Concentration Values for
the Unbound Prednisolone Base Model
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A one compartment model with a fixed first order absorption rate constant (k,=2.84 hr1), exponential interindividual variability, and a combined proportional and additive
residual error were used .
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Figure 24.

Normalized Clearance versus Time Post Transplant (Day) for Each

Patient Using Unbound Prednisolone Base Model Clearance Estimates
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A one compartment model with a fixed first order absorption rate constant (k.=2 .84 hr"
1
) , exponential interindividual variability, and a combined proportional and additive
residual error were used.
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Figure 25. Observed Prednisolone Plasma Concentration versus Predicted Prednisolone
Plasma Concentration Values for the Final Unbound Prednisolone Alone Model
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A one compartment model with a fixed first order absorption rate constant (k,=2.84 h(
1
) , exponential interindividual variability, and a combined proportional and additive
residual error were used .

178

Figure 26. Weighted Residuals versus Predicted Prednisolone Plasma Concentration
Values for the Final Prednisolone Unbound Alone Model
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A one compartment model with a fixed first order absorption rate constant (k.=2.84 hr1), exponential interindividual variability, and a combined proportional and additive
residual error were used .
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Figure 27. Observed versus Predicted Unbound Prednisolone and Total Prednisone
Concentrations for Model 5
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(

Figure 28. CL/F versus Cystic Fibrosis for Males not Using Ciprofloxacin (Final
Prednisolone Alone Model)
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Abbreviations: CL/F = oral clearance
A one compartment model with a fixed first order absorption rate constant (k.=2.84 hr"
1
) , exponential interindividual variability, and a combined proportional and additive
residual error were used.
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SUMMARY OF CONCLUSIONS

The population approach to pharmacokinetic analysis has become a common tool in the
drug development process. Two major advantages of this type of analysis are I) the
ability to pool data from a population from which it might otherwise be difficult to
collect information and 2) the ability to model sparse data. Thus, this approach can be
used to reduce the number of clinical trials that need to be conducted in order to obtain
alternate dosing information for sub-populations.

Azithromycin Model:
The azithromycin model was an example of an analysis that pooled data from multiple
clinical trials. Dosing information in various sub-populations of the pediatric patients
was analyzed without having to conduct more clinical trials. The objective of this
analysis was to develop a population pharmacokinetic model for 58 pediatric patients
taking azithromycin in four separate clinical trials. A two compartment model with
parallel zero-order and first-order absorption was found to best fit the data. When
standardized by the mean weight, the parameter values generally compared well for the
pediatric patients compared to values found in the adult population. Because of the
richness of the sample times collected in these studies, the FOCE approach was used to
determine the final model. Weight was found to be a significant covariate for both CL/F
and V2/F. The final model was an improvement over the base model as seen by
reductions in %RSE on parameter estimates, reductions in interindividual variability, a
reduction in the residual variability, and an improvement in the diagnostic plots. While
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the final model was an improvement, there was still bias and imprecision present in the
model. Additional model development pursuing a three compartment model may
address the bias and imprecision.

The final azithromycin model found in this analysis supports the current weight adjusted
dosing guidelines for azithromycin.

Prednisolone Model:
The prednisolone model was an example of an analysis that utilized sparse data collected
as a secondary endpoint in a clinical trial . The objective of this analysis was to develop
a population pharmacokinetic model from 41 thoracic organ transplant patients dosed
with prednisolone. Unbound prednisolone concentrations were estimated and found to
follow linear pharrnacokinetics. A one compartment model with a fixed absorption rate
constant of2.84 hr"' was found to best fit the unbound prednisolone concentration time
data. Sex and concomitant ciprofloxacin use were found to be significant covariates for
CL/F. The final model was an improvement over the base model as seen by reductions in
%RSE on parameter estimates, a reduction in the residual variability, and an
improvement in the diagnostic plots. The prednisolone and prednisone concentration
data were simultaneously modeled using final parameter estimates from the prednisolone
alone model and literature values for the VIF terms. Many models were developed, but
they all proved to be inadequate because of lack of robustness or lack of clinical
meaningfulness with our understanding of prednisolone/prednisone pharrnacokinetics.
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APPENDIX A

The following text provides additional information on the pharmacokinetics of
azithromycin.

The following figures provide additional information on the modeling process that was
employed in Manuscripts II and ill.

Figures 1-7 contain NONMEM control streams. For azithromycin, NONMEM was run
using the command prompt in MS-DOS (Figures 1-4). For prednisolone, NONMEM
was run using PDx-Pop (Figures 5-7). Figure 8 contains information regarding S-Plus
box and whisker plots.
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Azithromycin Pharmacokinetics
Absorption
Oral azithromycin has a bioavailability (F) of approximately 37% (1). In a study of
twelve patients that had ileostomies, it was found that slow or incomplete absorption
was the most important limitation on the bioavailability of azithromycin, as opposed to
acid degradation or extensive first-pass metabolism (2).

Azithromycin has a rapid rate of absorption with a peak concentration (Cmax) occurring
around 2-3 hours post dose (Tmax) (1;3).

Distribution
Azithromycin exhibits a rapid distribution into tissues. Azithromycin is actively
transported into cells and then slowly released into the extracellular fluid compartments
(4). There are significantly higher azithromycin concentrations in tissues than in plasma
or serum (10- to 100-fold) (I ;4-6).

Serum protein binding is low and variable. A bound fraction of0.5 has been observed
for serum concentration ranges of0.02-0.05 mg/L, and 0.7-0.12 for ranges of0.5-2.0
mg/L; lower concentrations of azithromycin exhibit greater protein binding (I ;4;5).
Azithromycin binds predominately to u 1-acid glycoprotein (1) .

The volume of distribution of azithromycin has been reported as being 23-33 Ukg (3-7).
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Metabolism
Metabolism is not a major route of elimination for azithromycin (2;4;8;9). When
azithromycin is metabolized, the primary route of metabolism is hepatic demethylation
(10). Unlike other macrolide antibiotics, there has been no evidence of cytochrome P450
induction or inhibition by azithromycin (9; 11 ; 12).

Excretion
Azithromycin is principally eliminated via the liver (5). The major route of elimination is
through biliary excretion, predominantly as unchanged drug ( 1;2;8;9). Over 50% of
drug related material in the bile is unchanged azithromycin (10) .

Urinary excretion of unchanged azithromycin appears to be a minor route of elimination
(<6%) (5 ;9; 10). The renal clearance of azithromycin is in the range of 6-11.34 L/h
(3 ;9;10). The plasma clearance ofazithromycin is in the range of37.8-39.9 L/h
(3 ;5;7;13 ;14).

Azithromycin has a half life around 55-70 hours (1;4;5;7;14). The apparent steady-state
volume of distribution (- 30 L/kg) and plasma clearance (- 38 L/h) suggest that the long
half-life is due to extensive distribution and subsequent release of drug from tissues
rather than to an intrinsic inability to clear azithromycin (5 ;7;13 ;14).
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Figure I . NONMEM Control File for Base Azithromycin Model - FO Method

$PROB AZITHROMYCIN PEDS 80% Additive Error - RUN BASE PEDS MODEL
$INPUT ID AMT TIME DATE ADDL II DV RATE
$DATA NOZERO.CSV IGNORE=C
$SUBROUTINE ADVAN4 TRANS4
$PK
TVCL=THETA(!)
TVV2=THETA(2)
TVQ=THETA(3)
TVV3=THETA(4)
TVKA=THET A(5)
TVRl=THETA(6)
CL=TVCL *EXP(ETA(l ))
V2=TVV2
Q=TVQ*EXP(ETA(2))
V3=TVV3 *EXP(ET A(3 ))
KA=TVKA*EXP(ETA(4))
Rl=TVRI
S2=V2
$ERROR
IPRED=F
IRES = DV - IPRED
Y = F*(l+EPS(l))
$THETA
(10, 100,300) ;CL
(100,200,500); V2
(50,150,400) ;Q
(1000,2900,4000) ;V3
(0,1,5) ;KA
(50, I 00,300);Rl
$OMEGA 0.25 0.25 0.25 0.25
$SIGMA0.25
$ESTIMATION MAXEYAL=9999 PRINT=5 POSTHOC METHOD=O
$COVARIANCE
$TABLE ID AMT TIME CL V2 V3 Q KA RI RES WRES PRED
IPRED IRES ETA! ETA2 ETA3 ETA4 NOPRJNT FILE=CLV3KAQ.TOI
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Figure 2. NONMEM Control File for Full Azithromycin Model - FO Method
$PROB AZITHROMYCIN PEDS 800/o Additive Error - RUN BASE PEDS MODEL
WI COVARIATES
$INPUT ID AMT TIME DATE ADDL II DV RATE RACE=DROP AGE HT=DROP
WT ANE=DROP CA=DROP PN=DROP NAU=DROP COL=DROP ALB AMI
CAP=DROP CEFA=DROP CEFR DIG=DROP DIP=DROP DOP FEN=DROP
LAS=DROP MOR NYS=DROP SUL=DROP TIC VAN VER=DROP
$DATA NOZEROCO.CSV IGNORE=C
$SUBROUTINE ADVAN4 TRANS4
$PK
TVCL=THETA(l )+THET A(7)*(WT)+ THETA(8)*(ALB)
TVV2=THETA(2)
TVQ=THETA(3)+THETA(l l)*(DOP)
TVV3=THETA(4)+THETA(9)*(CEFR)+THETA(lO)*(WT)
TVKA=THETA(5)+THETA(12)*MOR
TVRl =THETA(6)
CL=TVCL *EXP(ETA(l))
V2=TVV2
Q=TVQ*EXP(ETA(2))
V3=TVV3 ; *EXP(ET A(3))
KA=TVKA *EXP(ET A(3))
Rl =TVRl
S2=V2
$ERROR
IPRED = F
IRES = DV - IPRED
Y = F*(l +EPS(l ))
$THETA
(30,50,90) ;CL
(100,200,400); V2
(50, 100,300) ;Q
(800, 1000,2000) ;VJ
(1 ,2,4) ;KA
( 50, 100,200);R 1
(0,1 ,5) ; WT
(-40, -30, -10) ;ALB
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Figure 2. NONMEM Control for Full Model (con't)

(-800,-500,-300) ; CEFR
(0,30,50) ; WT
(1); DOP
(.0001); MOR
$OMEGA 0.25 0.25 0.25 ;0.25
$SIGMA0.25
$ESTIMATION MAXEY AL=9999 PRINT=5 POSTHOC METHOD=O
$COYARIANCE
$TABLE ID AMT TIME CL Y2 V3 Q KAR 1 RES WRES PRED
IPRED IRES ETA I ET A2 ETA3 NOPRINT FILE=MORKA.TOl
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Figure 3. NONMEM Control File for Final Azithromycin Model - FO Method
$PROB AZITHROMYCIN PEDS 100"/o data - Exp Error
$INPUT ID WT ALB CEFR DOP=DROP AMT TIME DATE ADDL II RATE DV
$DATA VALIDATE .CSV IGNORE=C
$SUBROUTINE ADVAN4 TRANS4
$PK
TVCL=THETA(l)+THETA(7)*(WT)+ THETA(8)*(ALB)
TVV2=THETA(2)
TVQ=THETA(3)
TVV3=THETA(4)+THETA(9)*(CEFR)+THETA(IO)*(WT)
TVKA=THETA(5)
TVRI =THETA(6)
CL=TVCL*EXP(ET A(!))
V2=TVV2
Q=TVQ*EXP(ETA(2))
V3=TVV3 *EXP(ETA(3))
KA=TVKA*EXP(ETA(4))
Rl=TVRI
S2=V2
$ERROR
IPRED=F
IRES = DV - IPRED
Y = F*(l+EPS(l))
$THETA
(0,50) ;CL
(100,200,500); V2
(50, 150,400) ;Q
(1000,2900,4000) ;V3
(0,1,5) ;KA
(50, I00,300);Rl
(0,50); WT
(I) ;ALB
(100); CEFR
(10); WT
$OMEGA 0.25 0.25 0.25 0.25
$SIGMA0.25
$ESTIMATION MAXEYAL=9999 PRINT=5 POSTHOC METHOD=O
$COYARIANCE
$TABLE ID AMT TIME CL V2 V3 Q KA RI RES WRES PRED WT ALB CEFR
IPRED IRES ET A I ET A2 ET A3 ET A4 NOPRINT FILE=V ALIDATE.TO I
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Figure 4. NONMEM Control File for Final Azithromycio Model - FOCE Method
$PROB AZITHROMYCIN PEDS 100"/o data - FOCE Method
$INPUT CID WT ALB CEFR DOP=DROP AMT TIME DATE ADDL II RATE DV
$DATA 002.CSV IGNORE=C
$SUBROUTINE ADVAN4 TRANS4
$PK
TVCL=TIIBTA(l)+TIIBTA(7)*(WT)
TVV2=TIIBTA(2)
TVQ=TIIBT A(3)
TVV3=TIIBTA(4)+TIIBTA(8)*(WT)
TVKA=TIIBTA(5)
TVRl =TIIBTA(6)
CL=TVCL*EXP(ET A(I}}
V2=TVV2
Q=TVQ
V3=TVV3
KA=TVKA *EXP(ETA(2))
Rl =TVRI
S2=V2
$ERROR
DEL=O
IF(F.EQ.O) DEL= I
W=F
IPRED=F
IRES=DV-IPRED
IWRES=IRES/(W+DEL)
Y=F+F*EPS(I}
$TIIBTA
(10,30,50) ;CL
(100,200,300); V2
(50, 150,300) ;Q
(600, 1000, 1500} ;V3
(. 5,2,3) ;KA
(50, I 00,250);RI
(0,5, 10) ; WT
(10,20,40) ; WT
$OMEGA 0.5 0.5
$SIGMA0.25
$ESTIMATION MAXEY AL=9999 PRINT=5 POSTHOC NO ABORT METHOD= I
$COYARIANCE
$TABLE ID AMT TIME CL V2 V3 Q KA RI RES WRES PRED WT IPRED IRES
ET Al ET A2 NOPRINT FILE=FOCE .TOI
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Figure 5. NONMEM Control File for Base Prednisolone Model
;Model Desc: linear code parent (KA=2.84, tmax=l , thalf-=3 .41 all data W/ FUALB)
;Project Name: pred
;Project ID : GM00-001
$PROB RUN# 228 (base model ka=2.84)
$INPUT CID DATE TIME DVT=DROP SRT2 AMT2=DROP AMT II ADDL EVID
CMT FU2=DROP FU DY
$DATA 005 .CSV IGNORE=C
$SUBROUTINES ADV AN2 TRANS2 SS2
$PK
TVCL=THETA( 1)
TVV=THETA(2)
TVKA=THET A(3)
CL=TVCL *EXP(ETA(l ))
V=TVV*EXP(ETA(2))
KA=TVKA
S2=V
$ERROR
DEL=O
IF(F.EQ.O) DEL= !
W=F
IPRED=F
IRES=DV-IPRED
IWRES=IRES/(W+DEL)
IF(CMT.EQ .2) THEN
Y=F+F*EPS(l )+EPS(2)
ENDIF
$THETA
(0, I 0, 1OO);CL
(50, 100, IOOO);VP
(2 .84 FIXED)
$OMEGA
0.25 ;[P] INTERIND VAR IN CL
0.25 ;[P] INTERIND VAR IN VP
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$SIGMA
0.1 ;[P]
0.1 ;[A]
$EST MAXEY AL=9999 PRINT=S METHOD=O POSTHOC
$COYARIANCE
$TABLE ID CL Y ETA! ET A2 RES WRES DY NOPRINT ONEHEADER
FILE=228.TAB
$TABLE ID CLY ETA! ET A2 RES WRES DY NOPRINT ONEHEADER
FILE=patab228.TAB
$TABLE ID CLY ETA! ET A2 RES WRES DY NOPRINT ONEHEADER
FILE=cotab228. TAB
$TABLE ID CL VET Al ET A2 RES WRES DY NOPRINT ONEHEADER
FILE=catab228.TAB
$TABLE ID CL V ETA! ET A2 RES WRES DY NOPRINT ONEHEADER
FILE=sdtab228.TAB
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Figure 6.

NONMEM Control File for Final Prednisolone Model

;Model Desc: parent FUALB SEX,CIPR ON CL, CEFO(DROP),
GANC(DROP),ITRA(DROP),ACYC(DROP) ON V
;Project Name: BACKPFUALB
;Project ID: JJOOI
$PROB RUN# 736 (PARENT SEX,CIPR ON CL)
$INPUT CID DATE OTPD=DROP NTPD=DROP TIME PDN=DROP PDL=DROP
DVT=DROP COR=DROP TOT=DROP SDOS=DROP DOSE=DROP SORT=DROP
PD I=DROP PD2=DROP AMT2=DROP AMT II ADDL EVID CMT TYPE
AGE=DROP SEX PDG=DROP WT=DROP GTTO=DROP GTT2=DROP
WBC=DROP HB=DROP NEUT=DROP L YM=DROP MONO=DROP BAS=DROP
EOS=DROP CRT=DROP ALB=DROP AUCM=DROP AUCP=DROP AUCC=DROP
AZA=DROP
MPD=DROP FLU=DROP CEFO CEFT=DROP IMIP=DROP CIPR ACYC GANC
AMPH=DROP ITRA LAB=DROP SEPT=DROP FU=DROP FUA=DROP
REA=DROP
CREA=DROP CCL2=DROP BILI=DROP Al=DROP CSY2=DROP SCRE=DROP CF
CRCL=DROP CSYC=DROP DY MENO=DROP
$DATA 007.CSV IGNORE=C
$SUBROUTINES ADVAN2 TRANS2 SS2
$PK
TVCL=THETA(l)+THETA(4)*SEX+THETA(5)*CIPR
TVV=THET A(2)
TVKA=THETA(3)
CL=TVCL *EXP(ETA( I))
V=TVV*EXP(ETA(2))
KA=TVKA
S2=V
$ERROR
DEL=O
IF(F.EQ.O) DEL= !
W=F
IPRED=F
IRES=DV-IPRED
IWRES=IRES/(W+DEL)
IF(CMT.EQ.2) THEN
Y=F+F*EPS(l )+EPS(2)
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ENDIF

$THETA
(10,20,60);CP
(100,400,SOO);VP
(2.84 FIXED)
(O, lO);SEX
(-lO);CIPR
$OMEGA
0.25 ;[P] INTERIND YAR IN CP
0.25 ;[P] INTERIND YAR IN VP
$SIGMA
0.1 ;[P]
0.1 ;(A]
$EST MAXEY AL=9999 PRINT=5 METHOD=O POSTHOC NO ABORT
$COYARIANCE
$TABLE ID CLY ETAI ETA2 SEX CIPR ITRA DATE RES WRES DY NOPRINT
ONEHEADER Fil..E=736.T AB
$TABLE ID CLY ET Al ETA2 SEX CIPR ITRA DATE RES WRES DY NOPRINT
ONEHEADER FILE=patab736.TAB
$TABLE ID CL YETAl ETA2 SEXCIPR ITRA DATE RES WRES DYNOPRINT
ONEHEADER FILE=cotab736.TAB
$TABLE ID CLY ETAl ETA2 SEX CIPR ITRA DATE RES WRES DY NOPRINT
ONEHEADER Fil..E=catab736.T AB
$TABLE ID CLY ET Al ETA2 SEX CIPR ITRA DATE RES WRES DYNOPRINT
ONEHEADER FILE=sdtab736.TAB
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Figure 7.

NONMEM Control File Example Using Nonlinear Rates for Prednisolone
and Prednisone Simultaneous Model - Model 6

;Model Desc: p&m - 2c model -non linear k23 , linear k32
;Project Name: METABOLITE
;Project ID: GM00-001
$PROB RUN# 521 (PARENT AND METABOLITE)
$INPUT C ID DATE OTPD=DROP NTPD=DROP TJME PDN=DROP PDL=DROP
DVT=DROP CORT=DROP TOT=DROP SDOS=DROP DOSE SORT=DROP
PDl=DROP PD2=DROP AMT2=DROP AMT II ADDL EVID CMT TYPE
AGE=DROP SEX PDG=DROP WT=DROP GTTO=DROP GTT2=DROP
WBC=DROP HB=DROP NEUT=DROP L YM=DROP MONO=DROP BAS=DROP
EOS=DROP CRT=DROP ALB=DROP AUCM=DROP AUCP=DROP AUCC=DROP
AZA=DROP
MPD=DROP FLU=DROP CEFO CEFT=DROP IMIP CIPR=DROP ACYC
ANC=DROP AMPH=DROP ITRA LAB=DROP SEPT=DROP FU=DROP
FUA=DROP UREA=DROP CREA=DROP CCL2=DROP BILI=DROP AJ =DROP
CSY2=DROP SCRE=DROP CF=DROP CRCL=DROP CSYC=DROP DY
$DATA 010.CSV IGNORE=C
$SUBROUTINES ADVAN6 TOL=3
$MODEL NP ARAM=7 NCOMP=3
COMP=(GUT, DEFDOSE)
COMP=(PARENT,DEFOBS)
COMP=(MET AB)
$PK
;CPM=THETA(l)*EXP(ETA(l))
CPR=THETA(J)*EXP(ETA(l))
VP=THETA(2)*EXP(ETA(2))
CLM=THETA(3)*EXP(ETA(3))
VM=THETA(4)*EXP(ETA(4))
VMAX=THET A(S)*EXP(ETA(S))
KM=THET A(6)*EXP(ETA(6))
S2=VP
S3=VM
Kl2=THETA(7)
K23=CPMNP
K32=CLM/VM
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K20=CPR/VP
$DES
DADT(l)=-Kl2*A(l)
DADT(2)=Kl2* A(l)-K20* A(2)-VMAX* A(2)/(KM*VP+A(2))+K32* A(3)
DADT(3)=VMAX* A(2)/(KM*VP+A(2))-K20* A(3)
$ERROR
DEL=O
IF(F.EQ.O) DEL=l
W=F
IPRED=F
IRES=DV-IPRED
IWRES=IRES/(W+DEL)
IF(CMT.EQ.2) THEN
Y=F+F*EPS(I )+EPS(2)
END IF
IF (CMT.EQ.3) THEN
Y=F+F*EPS(3)+EPS(4)
ENDIF
$THETA
(0,2,30);CPR
(420 FIXED);VP
(0,50, 1OO);CLM
(55 FIXED);VM
(0,6000);VMAX
(0, l 5000);KM
(2 .84 FIXED)
$OMEGA
0.001 ;[P] INTERIND VAR IN CPR
0.3 ;[P] INTERIND VAR IN VP
0.008 ;[P] INTERIND VAR IN CLM
0.008 ;[P] INTERIND VAR IN VM
0.001 ;[P]] INTERIND VAR IN VMAX
0.001 ;[P]] INTERIND VAR INKM
$SIGMA
0.1 ;[P]
0.1 ;[A]
0.1 ;[P]
0.1 ;[A]
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$EST MAXEYAL=9999 PRINT=S NOABORT POSTHOC
$COV
$TABLE ID VMAX KM CPR VP CLM VM K32 K20 ETA! ETA2 ETAJ
ETA4 RES WRES DV CMT IPRED IRES IWRES NOPRINT ONEHEADER
FILE=52 l .TAB
$TABLE ID VMAX KM CPR VP CLM VM K32 K20 ETA! ET A2 ETA3
ET A4 RES WRES DV CMT IPRED IRES IWRES NOPRINT ONEHEADER
FILE=patab521 .TAB
$TABLE ID VMAXKMCPR VPCLMVMK32K20ETAI ETA2ETA3
ETA4 RES WRES DV CMT IPRED IRES IWRES NOPRINT ONEHEADER
FILE=cotab52 l .TAB
$TABLE ID VMAXKMCPR VPCLMVMK32K20ETAI ETA2ETA3
ETA4 RES WRES DV CMT IPRED IRES IWRES NOPRINT ONEHEADER
FILE=catab521.TAB
$TABLE ID VMAXKM CPR VP CLM VMK32 K20 ETA! ETA2 ETAJ
ET A4 RES WRES DV CMT IPRED IRES IWRES NOPRINT ONEHEADER
FILE=sdtab521 .TAB
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Figure 8.

Explanation of S-Plus Box Plots using Manuscript II Figure 5
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The lower and upper lines of the box designate the 25 and 75"' percentile respectively.

The whiskers of the plot are the nearest value not beyond a standard span from the
quartiles. The standard span is calculated as I .5·interquartile range.

Lines outside of the box and whiskers are outliers.
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